Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2023

(Commission File No. 001-39431)

Freeline Therapeutics Holdings plc

(Exact Name of Registrant as Specified in Its Charter)

Sycamore House

Gunnels Wood Road

Stevenage, Hertfordshire SG1 2BP

United Kingdom

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This Report on Form 6-K (other than the information contained in the press release furnished as Exhibit 99.1 to this Report on Form 6-K) shall be deemed to be incorporated by reference into the registration statement on Form F-3 (File No. 333-259444) and registration statements on Form S-8 (File Nos. 333-242129, 333-242133, 333-259852 and 333-265634) of Freeline Therapeutics Holdings plc and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

The information contained in the press release furnished as Exhibit 99.1 to this Report on Form 6-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

INDEX


PART I
		Page
ITEM 1.	Financial Statements
	A. Unaudited Condensed Consolidated Balance Sheets	F-1
	B. Unaudited Condensed Consolidated Statements of Operations	F-2
	C. Unaudited Condensed Consolidated Statements of Comprehensive Loss	F-3
	D. Unaudited Condensed Consolidated Statements of Shareholders’ Equity	F-4
	E. Unaudited Condensed Consolidated Statements of Cash Flows	F-5
	Notes to Unaudited Condensed Consolidated Financial Statements	F-7

ITEM 2.	Special Note Regarding Forward-Looking Statements	1
	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3
	Risk Factors	14

PART II

ITEM 3.	Exhibits	18

FREELINE THERAPEUTICS HOLDINGS PLC

Unaudited Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

(expressed in U.S. Dollars, unless otherwise stated)


	September 30,			December 31,
	2023			2022
Assets
Current Assets:
Cash and cash equivalents	$	29,452		$	47,279
Prepaid expenses and other current assets		4,544			6,235
Assets held for sale		—			14,113
Total current assets		33,996			67,627
Non-current assets:
Property and equipment, net		8,625			9,007
Operating lease right of use assets		3,926			6,014
Other non-current assets		2,672			3,993
Total assets	$	49,219		$	86,641
Liabilities and shareholders' equity
Current Liabilities:
Accounts payable	$	7,778		$	10,058
Accrued expenses and other current liabilities		7,413			7,908
Operating lease liabilities, current		2,286			2,663
Liabilities related to assets held for sale		—			10,337
Total current liabilities		17,477			30,966
Non-current liabilities:
Operating lease liabilities, non-current		1,702			3,261
Total liabilities		19,179			34,227
Commitments and contingencies (Note 12)
Shareholders’ equity:
Ordinary shares, £0.00001 par value, 400,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 65,369,206 and 65,113,575 issued and outstanding as of September 30, 2023 and December 31, 2022, respectively		—			—
Deferred shares, £0.00001 par value; 37,613 and 24,812 shares authorized, issued and outstanding as of September 30, 2023 and December 31, 2022, respectively		—			—
Deferred shares, £100,000 par value; 1 authorized, issued and outstanding as of September 30, 2023 and December 31, 2022		137			137
Additional paid-in capital		503,756			500,781
Accumulated other comprehensive loss		(1,567	)		(3,151	)
Accumulated deficit		(472,286	)		(445,353	)
Total shareholders’ equity		30,040			52,414
Total liabilities and shareholders' equity	$	49,219		$	86,641

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-1

FREELINE THERAPEUTICS HOLDINGS PLC

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(expressed in U.S. Dollars, unless otherwise stated)


	For the Nine Months Ended September 30,
	2023			2022
License revenue	$	622		$	—
Operating expenses:
Research and development		25,508			53,561
General and administrative		24,001			25,009
Gain on legal settlement		(2,227	)		—
Restructuring expense		1,339			—
Total operating expenses		48,621			78,570
Loss from operations:		(47,999	)		(78,570	)
Other income, net:
Gain on sale of Freeline Therapeutics GmbH		20,279			—
Gain on lease termination		—			5,307
Other income, net		39			5,451
Interest income, net		338			631
Benefit from R&D tax credit		619			1,304
Total other income, net		21,275			12,693
Net loss before income taxes		(26,724	)		(65,877	)
Income tax expense		(209	)		(96	)
Net loss	$	(26,933	)	$	(65,973	)
Net loss per share attributable to ordinary shareholders—basic and diluted		(0.41	)		(1.15	)
Weighted average ordinary shares outstanding—basic and diluted		65,217,110			57,384,985

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-2

FREELINE THERAPEUTICS HOLDINGS PLC

Unaudited Condensed Consolidated Statements of Comprehensive Loss

(in thousands)

(expressed in U.S. Dollars, unless otherwise stated)


	For the Nine Months Ended September 30,
	2023			2022
Net loss	$	(26,933	)	$	(65,973	)
Other comprehensive loss:
Foreign currency translation adjustment		1,429			(18,324	)
Comprehensive loss	$	(25,504	)	$	(84,297	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-3

FREELINE THERAPEUTICS HOLDINGS PLC

Unaudited Condensed Consolidated Statements of Shareholders’ Equity

(in thousands, except share amounts)

(expressed in U.S. Dollars, unless otherwise stated)


	Ordinary £0.00001 Par Value					Deferred Shares £0.00001 Par Value					Deferred Shares £0.001 Par Value				Deferred Shares £100,000 Par Value				Additional Paid-in Capital		Accumulated other comprehensive gain (loss)			Accumulated			TOTAL SHAREHOLDERS'
	Shares			Amount		Shares			Amount		Shares		Amount		Shares		Amount		Amount		Amount			Deficit			Equity
Balance at December 31, 2021		35,854,591		$	—		112,077		$	—		—	$	—		1	$	137	$	467,213	$	9,472		$	(356,381	)	$	120,441
Shares issued under employee share purchase plan		149,254			—		—			—		—		—		—		—		110		—			—			110
Vesting of restricted share units		34,063			—		—			—		—		—		—		—		—		—			—			—
Forfeiture of ordinary shares		(5,477	)		—		5,477							—		—		—		—		—			—			—
Issuance of ordinary shares, net of issuance cost of $2,600		28,848,968			—		—			—		—		—		—		—		28,291		—			—			28,291
Cancellation of deferred shares		—			—		(93,451	)		—		—		—		—		—		—		—			—
Non-cash share-based compensation		—			—		—			—		—		—		—		—		4,037		—			—			4,037
Unrealized loss on foreign currency translation		—			—		—			—		—		—		—		—		—		(18,324	)		—			(18,324	)
Net loss		—			—		—			—		—		—		—		—		—		—			(65,973	)		(65,973	)
Balance at September 30, 2022		64,881,399		$	—		24,103		$	—		—	$	—		1	$	137	$	499,651	$	(8,852	)	$	(422,354	)	$	68,582


Balance at December 31, 2022		65,113,575		$	—		24,812		$	—		—	$	—		1	$	137	$	500,781	$	(3,151	)	$	(445,353	)	$	52,414
Shares issued under employee share purchase plan		217,755			—		—			—		—		—		—		—		32		—			—			32
Vesting of restricted share units		50,677			—		—			—		—		—		—		—		—		—			—			—
Forfeiture of ordinary shares		(12,801	)		—		12,801							—		—		—		—		—			—			—
Non-cash share-based compensation		—			—		—			—		—		—		—		—		2,943		—			—			2,943
Release of cumulative foreign currency translation adjustment, upon sale of Freeline Therapeutics GmbH		—			—		—			—		—		—		—		—		—		155			—			155
Unrealized gain on foreign currency translation		—			—		—			—		—		—		—		—		—		1,429			—			1,429
Net loss		—			—		—			—		—		—		—		—		—		—			(26,933	)		(26,933	)
Balance at September 30, 2023		65,369,206		$	—		37,613		$	—		—	$	—		1	$	137	$	503,756	$	(1,567	)	$	(472,286	)	$	30,040

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-4

FREELINE THERAPEUTICS HOLDINGS PLC

Unaudited Condensed Consolidated Statements of Cash Flows

(in thousands)

(expressed in U.S. Dollars, unless otherwise stated)


	For the Nine Months Ended September 30,
	2023			2022
Cash flows from operating activities:
Net loss	$	(26,933	)	$	(65,973	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		1,139			1,426
Non-cash share-based compensation expense		2,943			4,037
(Gain) loss on disposal of property and equipment		(47	)		238
Gain on sale of Freeline Therapeutics GmbH		(20,279	)		—
Gain on legal settlement		(2,227	)		—
Gain on lease termination		—			(5,307	)
Changes in components of operating assets and liabilities
Prepaids and other current assets		916			(1,917	)
Other non-current assets		—			(162	)
Operating lease right of use assets		2,180			46,594
Accounts payable		518			5,217
Accrued expenses and other current liabilities		(440	)		(4,110	)
Operating lease liabilities, net		(2,162	)		(38,416	)
Net cash used in operating activities		(44,392	)		(58,373	)
Cash flows from investing activities:
Purchase of property and equipment		(654	)		(3,117	)
Proceeds from the sale of equipment		62			—
Proceeds from the sale of Freeline Therapeutics GmbH, net of cash transferred with sale of $1,015		24,203			—
Net cash provided by (used in) investing activities		23,611			(3,117	)
Cash flows from financing activities:
Proceeds from issuance of ordinary shares		—			27,328
Proceeds from employee share purchase plan		32			107
Net cash provided by financing activities		32			27,435
Effect of exchange rate changes on cash, cash equivalents and restricted cash		1,292			(17,949	)
Net decrease in cash, cash equivalents and restricted cash		(19,457	)		(52,004	)
Cash, cash equivalents and restricted cash
Beginning of period		48,909			119,063
End of period	$	29,452		$	67,059
Supplemental disclosure of non-cash flow information:
Commitment shares issued to Lincoln Park Capital Fund, LLC		—			963
Property and equipment unpaid and accrued		35			1,221

The following table provides a reconciliation of the cash, cash equivalents and restricted cash balances as of each of the periods shown above:

F-5


	For the Nine Months Ended September 30,
	2023		2022
Cash and cash equivalents	$	29,452	$	65,848
Long-term restricted cash		—		1,211
Total cash, cash equivalents and restricted cash	$	29,452	$	67,059

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

F-6

FREELINE THERAPEUTICS HOLDINGS PLC

Notes to Unaudited Condensed Consolidated Financial Statements

Nature of the Business

Freeline Therapeutics Holdings plc (the “Company”) is a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated gene therapies for patients suffering from chronic debilitating diseases. The Company is headquartered in the United Kingdom (“U.K.”) and has operations in the United States (“U.S.”). The Company is a public limited company incorporated pursuant to the laws of England and Wales.

Going Concern

In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern.

The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, the ability to secure additional capital to fund operations, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with government regulations. Product candidates currently under development require significant additional research and development efforts, including clinical testing and regulatory approval, prior to any commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from any product sales.

The Company has funded its operations primarily with proceeds from the sale of its equity securities. As of September 30, 2023, the Company had unrestricted cash and cash equivalents of $29.5 million. The Company has incurred recurring losses since its inception including net losses of $26.9 million and $66.0 million for the nine months ended September 30, 2023 and 2022, respectively. In addition, the Company had an accumulated deficit of $472.3 million as of September 30, 2023.

Net cash used in operating and investing activities was $20.8 million for the nine months ended September 30, 2023. The Company expects to continue to incur significant expenses and generate operating losses for the foreseeable future. These conditions indicate that there is substantial doubt regarding the Company's ability to continue as a going concern for at least 12 months from the issuance date of these unaudited condensed consolidated financial statements.

As a result, the Company will need additional funding to support its continuing operations. There can be no assurances, however, that additional funding will be available on favorable terms, or at all. If adequate funds are not available, the Company will be required to further reduce headcount as well as spending and potentially delay, limit, reduce or terminate its product research and development efforts in order to enable it to meet its obligations as they fall due for the foreseeable future.

The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements as of and for the year ended December 31, 2022 in the Annual Report on Form 20-F. There have been no material changes to the significant accounting policies during the nine months ended September 30, 2023, except as described below.

F-7

License Revenue

The Company accounts for its revenues pursuant to the provisions of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”).

The Company has no products approved for commercial sale and has not generated any revenue from commercial product sales. The revenue earned to date has been generated solely from an out-licensing agreement.

In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the arrangement within the scope of ASC 606, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

License Fees and Multiple Element Arrangements

If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license at such time as the license is transferred to the licensee and the licensee is able to use, and benefit from, the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Appropriate methods of measuring progress include output methods and input methods. In determining the appropriate method for measuring progress, the Company considers the nature of service that the Company promises to transfer to the customer. When the Company decides on a method of measurement, the Company will apply that single method of measuring progress for each performance obligation satisfied over time and will apply that method consistently to similar performance obligations and in similar circumstances.

Contingent Research Milestone Payments

ASC 606 constrains the amount of variable consideration included in the transaction price in that either all, or a portion, of an amount of variable consideration should be included in the transaction price. The variable consideration amount should be included only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The assessment of whether variable consideration should be constrained is largely a qualitative one that has two elements: the likelihood of a change in estimate, and the magnitude thereof. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized is not significant.

If the consideration in a contract includes a variable amount, the Company will estimate the amount of consideration in exchange for transfer of promised goods or services. The consideration also can vary if the Company’s entitlement to the consideration is contingent on the occurrence or non-occurrence of a future event. The Company considers contingent research milestone payments to fall under the scope of variable consideration, which should be estimated for revenue recognition purposes at the inception of the contract and reassessed ongoing at the end of each reporting period. If the Company determines that variable consideration should be constrained, the variable consideration is not included as part of the transaction price. This includes an assessment of the probability that all or some of the milestone revenue could be reversed when the uncertainty around whether or not the achievement of each milestone is resolved, and the amount of reversal could be significant.

The Company considers all relevant factors in accordance with U.S. GAAP when assessing whether variable consideration should be constrained and no one factor is determinative.

F-8

Royalty Revenue

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and in which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

Sale of Freeline Therapeutics GmbH

On February 8, 2023, the Company sold its German subsidiary, Freeline Therapeutics GmbH, and certain intellectual property rights to Ascend Gene & Cell Therapies Limited ("Ascend") pursuant to a definitive agreement entered into in November 2022 for an aggregate cash purchase price of $25.0 million, subject to purchase price adjustments, and a license back of certain intellectual property rights assigned to Ascend (the "Subsidiary Sale"). The Subsidiary Sale did not meet the criteria for reporting discontinued operations as there was not a strategic shift that has had, or will have, a major effect on the Company's operations. The Company recognized a gain on the Subsidiary Sale of $20.3 million in its unaudited condensed consolidated statement of operations during the nine months ended September 30, 2023. Upon the closing of the Subsidiary Sale, the cumulative foreign currency translation losses totaling $0.2 million were released to earnings and included in the gain on the Subsidiary Sale.

In connection with the Subsidiary Sale, the Company and Ascend also entered into a transition services agreement (the "Transition Services Agreement"), pursuant to which Ascend will provide certain services in the area of development and manufacturing to the Company. As part of the Transition Services Agreement, the Company agreed to utilize no fewer than 15 full-time employee equivalents ("FTEs") per annum for a guaranteed period of 18 months following the Transition Services Agreement’s effective date of February 8, 2023. The Company also agreed to pay Ascend a guaranteed minimum of approximately $7.9 million in respect of FTE costs during such period, of which $2.6 million has been paid through September 30, 2023. The Company will make minimum guaranteed payments to Ascend of $2.2 million and $3.1 million for the years ending December 31, 2023 and 2024, respectively. The Transition Services Agreement will terminate three years after its effective date, unless earlier terminated by Freeline with 90 days' written notice, effective from the end of the 18-month guarantee period at the earliest, in accordance with its terms.

Concurrently with the closing of the Subsidiary Sale, the Company and Ascend entered into an intellectual property deed of assignment and license (the "IP Agreement"), pursuant to which the Company assigned certain intellectual property rights pertaining to the business of Freeline Therapeutics GmbH to Ascend, including certain patents and know-how related to chemistry, manufacturing and controls capabilities and technologies. Ascend granted a non-exclusive, royalty-free, perpetual, irrevocable, worldwide license back to the Company of the assigned rights necessary to develop or commercialize its then-current product candidates. There was no value assigned or recorded for the license back to the Company as the license is considered in-process research and development and had no alternative future use.

F-9

The table below sets forth the book value of the Freeline Therapeutics GmbH assets and liabilities sold along with the calculation of the gain on sale based on the cash consideration received.


	(in thousands)
Book value of assets sold
Cash and cash equivalents	$	1,015
Prepaid expenses and other current assets		414
Property and equipment, net		5,470
Operating lease right of use assets		8,455
Other non-current assets		3
Amounts attributable to assets sold		15,357
Book value of liabilities sold
Accounts payable		230
Accrued expenses and other current liabilities		1,430
Operating lease liabilities, current		869
Operating lease liabilities, non-current		8,044
Amounts attributable to liabilities sold		10,573
Total identifiable net assets sold		4,784
Less: accumulated other comprehensive loss		(155	)
Consideration, inclusive of cash transferred		25,218
Gain on sale of Freeline Therapeutics GmbH	$	20,279

License Revenue

On March 24, 2023, the Company entered into an exclusive patent and know-how out-license agreement (the "Syncona Agreement") with Syncona IP Holdco (2) Limited ("Syncona Holdco"), a company controlled by Syncona Limited. Under the terms of the Syncona Agreement, the Company granted Syncona Holdco an exclusive license under certain patent rights related to an immune-modifying protein (the "Patent"), an exclusive license under certain patent rights related to an assay (the "Assay Patent"), and a non-exclusive license to certain know-how (the "Assay Know-How") to develop and commercialize the technology other than in respect of liver-directed gene therapies. Upon execution of the Syncona Agreement, the Company made available the licensed intellectual property to Syncona Holdco for an upfront non-refundable payment of £0.5 million or $0.6 million. The Company has no further material performance obligations related to the Syncona Agreement.

The Company identified the following material promises relating to the Syncona Agreement. The Company determined that the licenses of the Patent, Assay Patent and Assay Know-How were not individually distinct because Syncona Holdco can only benefit from the licensed intellectual property rights when bundled together as one performance obligation. Based on these determinations, the Company identified one distinct performance obligation at the inception of the contract.

The Company further determined that the upfront license fee payable constitutes the transaction price at contract inception, which was allocated to one performance obligation. The amount of the transaction price allocated to the performance obligation is recognized as or when the Company satisfies the performance obligation. The Company determined that the performance obligation was recognized at a point-in-time, upon the delivery of the licenses to Syncona Holdco. The Company recognized total license revenue of £0.5 million or $0.6 million, related to the Syncona Agreement for the nine months ended September 30, 2023.

F-10

The Company may receive further payments up to £12.5 million or $15.6 million upon the achievement of certain development and regulatory milestones, as well as low-single-digit percentage royalty payments based on net sales of certain licensed products covered by the licensed intellectual property. Future potential milestone payments have not been recognized as revenue due to the risk of significant revenue reversal related to these amounts has not yet been resolved as of September 30, 2023. The achievement of the future potential milestones is not within the Company’s control and is subject to certain research and development success or regulatory approvals and therefore carries significant uncertainty. The Company will reevaluate the likelihood of achieving future milestones at the end of each reporting period. As all performance obligations will have been satisfied in advance of the achievement of the milestone events, if the risk of significant revenue reversal is resolved, any future milestone revenue from the arrangement will be added to the transaction price (and thereby recognized as revenue) in the period the risk is resolved.

The Company further granted to Syncona Holdco the option to take an assignment of the licensed intellectual property (the "Option"). Upon exercise of the Option, Syncona Holdco granted the Company a worldwide exclusive fully-paid up royalty free license to the assigned intellectual property. The Company determined that the Option is not considered a material right and does not give rise to a separate performance obligation. Syncona Holdco exercised the Option in July 2023.

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):


	September 30,		December 31,
	2023		2022
U.K. R&D tax credit	$	1,847	$	1,230
VAT receivable		976		1,373
Insurance		20		1,702
Prepaid clinical research organization costs		748		1,535
Other current assets		953		395
	$	4,544	$	6,235

Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):


	September 30,			December 31,
	2023			2022
Office equipment and computers	$	929		$	751
Furniture & Fixtures		2,586			2,584
Laboratory equipment		3,278			3,140
Leasehold improvements		7,887			7,549
		14,680			14,024
Less: accumulated depreciation		(6,055	)		(5,017	)
	$	8,625		$	9,007

Depreciation and amortization expense was $1.1 million and $1.4 million for the nine months ended September 30, 2023 and 2022, respectively.

F-11

Other Non-current Assets

Other non-current assets consisted of the following (in thousands):


	September 30,		December 31,
	2023		2022
Deferred offering costs	$	2,149	$	2,133
Restricted cash		—		1,327
Deferred tax asset		523		533
	$	2,672	$	3,993

Restricted cash consisted of collateral deposits for the office space leased by the Company's former wholly owned subsidiary, Freeline Therapeutics GmbH. This collateral was released upon the sale of Freeline Therapeutics GmbH in the nine months ended September 30, 2023.

Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consisted of the following (in thousands):


	September 30,		December 31,
	2023		2022
Employee compensation and benefits costs	$	2,743	$	4,178
Research and development expenses		3,036		1,923
Consulting and professional services		1,351		1,215
Other liabilities		283		592
	$	7,413	$	7,908

Shareholders’ Equity

Ordinary Shares

As of September 30, 2023, the Company’s authorized capital consisted of 400,000,000 ordinary shares with a par value of £0.00001 per share.

Each holder of ordinary shares is entitled to one vote per ordinary share and to receive dividends when and if such dividends are recommended by the board of directors and approved by the shareholders. As of September 30, 2023, the Company has not declared any dividends.

ADS Ratio Change

On May 12, 2023, the Company changed the ratio of its American Depositary Shares ("ADSs") to its ordinary shares (the "ADS Ratio") from the previous ADS Ratio of one ADS to one ordinary share to a new ADS Ratio of one ADS to fifteen ordinary shares. The change in the ADS Ratio had the same effect as a one-for-fifteen reverse ADS split and enabled the Company to regain compliance with the Nasdaq minimum bid price requirement. As all financial statement and disclosure information is presented in ordinary share amounts, not ADSs, there was no impact to the unaudited condensed consolidated financial statements and footnote disclosures. The Company paid depositary fees of $2.0 million in connection with the ADS Ratio change which is recorded within general and administrative expenses on the Company’s unaudited condensed consolidated statements of operations during the nine months ended September 30, 2023.

Registered Direct Offering

On March 10, 2022, the Company entered into a purchase agreement with its majority shareholder, Syncona Portfolio Limited, a subsidiary of Syncona Limited, and certain other existing shareholders providing for the issuance and sale by the Company of ADSs representing 24,857,144 ordinary shares at a price of $1.05 per ordinary share for total gross proceeds of $26.1 million, in a registered direct offering. The offering closed on March 15, 2022. The Company received net proceeds of approximately $24.2 million from the offering, after deducting offering expenses payable by the Company.

F-12

Lincoln Park Capital

On March 18, 2022, the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) under which the Company may at its discretion, sell to Lincoln Park up to $35.0 million of its ADSs over a 36-month period, subject to certain daily limits, applicable prices, and conditions. In addition, under the purchase agreement, the Company issued ADSs representing 954,208 ordinary shares as commitment shares to Lincoln Park as consideration for its commitment to purchase ADSs under the purchase agreement (the “Commitment Shares”). The Commitment Shares were valued using the closing price of the Company’s ADSs on the date of the purchase agreement resulting in a fair market value of approximately $1.0 million. The fair value of the Commitment Shares as well as issuance costs of $0.2 million associated with the purchase agreement are classified as other non-current assets in the accompanying unaudited condensed consolidated balance sheet. As the Company’s ADSs are sold in accordance with the purchase agreement, the fair value of the Commitment Shares and issuance costs will be reclassified to additional paid-in capital on the Company’s condensed consolidated balance sheet. During the nine months ended September 30, 2023, the Company did not issue any additional ADSs pursuant to the purchase agreement.

Open Market Sale AgreementSM

On November 17, 2021, the Company entered into an Open Market Sale AgreementSM (the "Sales Agreement") with Jefferies LLC ("Jefferies") pursuant to which the Company may issue and sell ADSs having aggregate offering sales proceeds of up to $75.0 million, from time to time, in “at-the-market” offerings pursuant to which Jefferies will act as sales agent and/or principal. During the year ended December 31, 2022, the Company issued ADSs representing 3,037,616 ordinary shares pursuant to the Sales Agreement, raising approximately $3.2 million in net proceeds. During the nine months ended September 30, 2023, the Company did not issue any additional ADSs pursuant to the Sales Agreement.

Deferred Shares

Deferred shares are a unit of equity that confer to their holder effectively no economic rights or any voting rights. The Company, without the consent of the shareholder, may transfer deferred shares at any time for nil consideration.

In the nine months ended September 30, 2023, unvested Employee Shares were forfeited upon termination of employment, classified as additional deferred shares of £0.00001 each on the balance sheet and will be subsequently cancelled (see Note 10).

Deferred shares are not included in the Company’s potentially dilutive securities as they are not ordinary shares and have no conversion rights.

The table below reflects the number of ordinary shares and deferred shares issued and outstanding at September 30, 2023 and December 31, 2022.


	September 30,		December 31,
	2023		2022
Ordinary shares		65,369,206		65,113,575
Deferred shares of £0.00001		37,613		24,812
Deferred shares of £100,000		1		1
Total ordinary and deferred shares		65,406,820		65,138,388

F-13

10.

Non-Cash Share-Based Compensation

2020 Equity Incentive Plan

On July 31, 2020, the Company adopted an equity incentive plan (the “2020 Plan”). The 2020 Plan provides for the grant of options, share appreciation rights (“SARs”), restricted shares, dividend equivalents, restricted share units (“RSUs”), and other share-based awards. The maximum number of equity awards originally authorized under the 2020 Plan was 5,898,625 shares. Additionally, the number of ordinary shares reserved for issuance under the 2020 Plan automatically increases on January 1st of each year, for a period of not more than ten years, by an amount equal to the lesser of (i) 4% of the total number of ordinary shares outstanding on December 31st of the prior calendar year or (ii) such fewer number of ordinary shares as the board of directors may designate prior to the applicable January 1st date. On January 1, 2023 and 2022, the number of shares reserved automatically increased by 2,596,620 and 1,434,184 shares, respectively. As of September 30, 2023, 2,252,316 shares are available for future issuance under the 2020 Plan.

The Company has typically granted equity awards under the 2020 Plan that vest over a four-year service period, with 25% of the award vesting on the first anniversary of the vesting commencement date, with the balance generally vesting periodically over the remaining three years. During the nine months ended September 30, 2023, the Company granted equity awards under the 2020 Plan that vest over a three-year service period, subject to vesting acceleration upon achievement of two distinct milestones related to progression of the Company’s FLT201 product candidate for the treatment of Gaucher disease Type 1 toward initiation of a Phase 3 clinical trial. See Note 15, Subsequent Events regarding achievement of performance milestones.

2021 Equity Inducement Plan

On September 27, 2021, the Company adopted an equity inducement plan (the “Inducement Plan”). The purpose of the Inducement Plan is to enhance the Company’s ability to attract employees who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Awards under the Inducement Plan are granted as an inducement material to employees entering into employment with the Company. The Inducement Plan provides for the grant of options, SARs, restricted shares, dividend equivalents, RSUs, and other share-based awards. The maximum number of equity awards authorized under the Inducement Plan is 3,400,000 shares. Any equity awards granted under the Inducement Plan that expire, lapse, or are terminated, exchanged for cash, surrendered, repurchased or cancelled, without having been fully exercised, or forfeited, will be added back to shares issuable under the Inducement Plan, subject to certain conditions. As of September 30, 2023, 1,677,200 shares are available for future issuance under the Inducement Plan. There were no inducement grants issued under the Inducement Plan during the nine months ended September 30, 2023.

2020 Employee Share Purchase Plan

On July 31, 2020, the Company adopted an employee share purchase plan (the “ESPP”). The purpose of the ESPP is to provide employees the opportunity to purchase ordinary shares or ADSs at 85% of the fair market value of the ADSs on the offering date or the exercise date, whichever is lower, for up to 15% of such employee’s compensation for each pay period. The Company reserved 347,447 ordinary shares for the ESPP. The ESPP provides for an annual increase beginning on January 1, 2022 in an amount equal to the least of (i) 347,447 ordinary shares, (ii) 1% of the total number of ordinary shares outstanding on December 31st of the prior calendar year or (iii) such fewer number of ordinary shares as the board of directors may designate prior to the applicable January 1st date. On January 1, 2023, the reserve automatically increased by 347,447 shares. During the nine months ended September 30, 2023, 217,755 shares were purchased under the ESPP. As of September 30, 2023, 393,278 shares are available for future issuance under the ESPP.

The numbers of Employee Shares, share options and RSUs, the weighted average grant date fair values per Employee Share, share option and RSU, and the weighted average exercise prices are all shown below on a per ordinary share basis.

F-14

Option Repricing

On June 28, 2023, the Company's shareholders approved the amendment of the exercise price of each outstanding option granted to an employee on or after June 1, 2021 with an exercise price greater than or equal to $0.42 per ordinary share (or $6.27 per ADS) under the 2021 Equity Inducement Plan and 2020 Equity Incentive Plan (the "In-Scope Options") to a new replacement exercise price per ADS equal to $2.42, the closing sales price for ADSs as quoted on the Nasdaq Capital Market on June 29, 2023 (the "Repricing"). The Repricing was effective on June 30, 2023 (the "Repricing Date"). Share options held by the Company's non-executive directors were not included in the Repricing. The Repricing was deemed to be a Type I modification event under ASC 718, Compensation-Stock Compensation. No other terms of the In-Scope Options were modified, and the In-Scope Options will continue to vest according to their original vesting schedules and will retain their original expiration dates. The Repricing resulted in incremental share-based compensation expense of $0.4 million, of which $0.1 million related to vested share option awards and was expensed on the Repricing Date and $0.3 million related to unvested share option awards and will be amortized on a ratable basis over the remaining weighted-average vesting period of those awards.

Employee Shares

The Company measures all non-cash share-based awards using the fair value on the date of grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. Prior to the Company’s initial public offering (“IPO”), the Company granted share-based compensation in the form of ordinary shares, collectively referred to as Employee Shares, to employees and non-employees with both performance and service-based vesting conditions. The Company records expense for these awards using the straight-line method.

A summary of the changes in the Employee Shares from December 31, 2022 through September 30, 2023 is as follows:


	Number of Shares			Weighted Average Grant Date Fair Value
Unvested balance as of December 31, 2022		16,309		$	11.33
Granted		—			—
Vested		(3,864	)		11.07
Forfeited		(11,642	)		11.91
Unvested balance as of September 30, 2023		803		$	13.05

As of September 30, 2023, there was less than $0.1 million of unrecognized compensation cost related to unvested Employee Shares outstanding, which is expected to be recognized over a weighted-average period of 1.0 years. Unvested Employee Shares are forfeited upon termination of employment, classified as deferred shares on the balance sheet and are subsequently cancelled.

Share Options Valuation

The assumptions used in the Black-Scholes option pricing model to determine the fair value of the share options granted to employees and directors during the nine months ended September 30, 2023 were as follows:


	For the Nine Months Ended September 30,
	2023
Expected option life (years)		5.8
Expected volatility		71.8	%
Risk-free interest rate		3.6	%
Expected dividend yield		—

F-15

Share Options


	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2022		7,918,500		$	4.76		8.40	$	—
Granted		4,031,696			0.20		—		457
Exercised		—			—		—		—
Expired		(665,081	)		13.67		—		—
Canceled or Forfeited		(1,789,783	)		2.86		—		—
Outstanding as of September 30, 2023		9,495,332		$	1.80		8.17	$	995
Exercisable as of September 30, 2023		3,017,640			4.48		6.53		211
Vested and expected to vest as of September 30, 2023		9,495,332		$	1.80		8.17	$	995

The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company’s ordinary shares for those share options that had exercise prices lower than the fair value of the Company’s ordinary shares.

The weighted-average grant-date fair value for the share options granted during the nine months ended September 30, 2023 and 2022 was $0.20 per share and $0.73 per share, respectively. The weighted-average grant-date fair value for the share options vested during the nine months ended September 30, 2023 and 2022 was $2.81 per share and $7.30 per share, respectively.

As of September 30, 2023, there was $5.5 million of unrecognized compensation cost related to unvested share options outstanding, which is expected to be recognized over a weighted-average period of 2.2 years.

Restricted Share Units

The Company has granted (i) RSUs that generally vest over a period of three or four years from the date of grant and (ii) RSUs to certain new employees in order to compensate them for equity awards forfeited to their previous employers which generally vest over a period of less than one year from the date of grant. The Company granted share options and RSUs as its annual equity incentive awards to employees during the nine months ended September 30, 2023. The following table summarizes the activity related to RSUs from December 31, 2022, through September 30, 2023:


	Number of RSUs			Weighted Average Grant Date Fair Value
Outstanding as of December 31, 2022		445,590		$	0.98
Granted		1,165,939			0.59
Vested and settled		(89,277	)		1.09
Canceled or forfeited		(351,821	)		0.85
Outstanding as of September 30, 2023		1,170,431		$	0.62

As of September 30, 2023, there was $0.6 million of unrecognized compensation cost related to unvested RSUs, which is expected to be recognized over a weighted-average period of 2.6 years.

F-16

Share-based Compensation Expense

Non-cash share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):


	For the Nine Months Ended September 30,
	2023		2022
Research and development	$	792	$	1,675
General and administrative		2,151		2,362
	$	2,943	$	4,037

11.

Net Loss Per Share

Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts):


	September 30,
	2023			2022
Numerator
Net loss	$	(26,933	)	$	(65,973	)
Net loss attributable to ordinary shareholders—basic and diluted	$	(26,933	)	$	(65,973	)
Denominator
Weighted-average number of ordinary shares used in net loss per share - basic and diluted		65,217,110			57,384,985
Net loss per share attributable to ordinary shareholders— basic and diluted	$	(0.41	)	$	(1.15	)

The Company used the treasury stock method to determine the number of dilutive shares. The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the nine months ended September 30, 2023 and 2022 because including them would have had an anti-dilutive effect:


	September 30,
	2023		2022
Unvested ordinary shares		803		21,493
Share options		9,495,332		8,171,164
Restricted share units		1,170,431		459,450
Total		10,666,566		8,652,107

12.

Commitments and Contingencies

Legal Proceedings

From time to time, the Company may be a party to litigation or arbitration or subject to claims incident to the ordinary course of business. Regardless of the outcome, litigation and arbitration are subject to inherent uncertainties and could adversely impact the Company’s reputation, operations, and its operating results or overall financial condition. As of September 30, 2023, except as set forth below, there were no pending material legal proceedings to which the Company was a party or to which any of its property was subject, and the Company did not have contingency reserves established for any liabilities as of September 30, 2023 and December 31, 2022. When appropriate in management’s estimation, the Company will record adequate reserves in its financial statements for pending litigation or arbitration.

F-17

In June 2020, the Company entered into a dedicated manufacturing and commercial supply agreement (the “Manufacturing Agreement”) with Brammer Bio MA, LLC (“Brammer”) pursuant to which Brammer was obligated to reserve certain amounts of manufacturing capacity in its manufacturing facility to supply the Company with its product candidate FLT180a for the treatment of hemophilia B. As consideration for the reserved manufacturing capacity, the Company was required to pay Brammer an annual capacity access fee of $10.0 million, subject to inflationary annual increases, excluding any purchase commitment or other fees.

The Company committed to an annual minimum purchase commitment equivalent to $6.0 million throughout the term of the Manufacturing Agreement. The term of the Manufacturing Agreement was effective as of June 30, 2020 and was to continue until December 31, 2027.

On May 18, 2023, the Company entered into a Mutual Release and Settlement Agreement (the "Settlement Agreement") with Brammer to resolve the Company’s claims and Brammer’s counterclaims in an arbitration brought by the Company before the American Arbitration Association in New York arising from the Manufacturing Agreement. Pursuant to the terms of the Settlement Agreement, the Company paid to Brammer a total of $2.25 million. Subject to specified conditions and exceptions, the parties dismissed the arbitration, and each party released the other party from any and all claims arising from the parties’ business relationship. As a result of the Settlement Agreement, the Company reversed $5.1 million of discharged liabilities and $0.6 million of prepaid expenses, which resulted in a net gain on legal settlement of $2.2 million on the unaudited condensed consolidated statements of operations.

As a result of the mutual termination of the Manufacturing Agreement in August 2022, the Company derecognized the associated operating lease assets and liabilities (see "Operating Lease Agreements" below) and no longer recognizes the annual minimum purchase commitment as a contractual obligation.

Operating Lease Agreements

The following table summarizes the Company’s costs included in the statements of operations related to right of use lease assets entered into through September 30, 2023 and 2022 (in thousands):


	For the Nine Months Ended September 30,
Lease Cost	2023			2022
Operating lease cost
Research and development	$	1,744		$	10,459
General and administrative		815			237
Short-term lease cost		60			217
Sublease income		(50	)		(186	)
Total lease cost	$	2,569		$	10,727



	For the Nine Months Ended September 30,
Other Information	2023			2022
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	2,309		$	9,301
Weighted-average remaining lease term-operating leases		6.50			6.90
Weighted-average discount rate-operating leases		10.89	%		7.28	%

In August 2022, in connection with the termination of the Manufacturing Agreement, the Company terminated the operating lease in connection with the dedicated capacity at the Brammer facility. The Company derecognized the related right-of-use asset of approximately $35.6 million and accordingly the operating lease liabilities of $40.3 million, resulting in a gain of $5.3 million classified as other income in the consolidated statement of operations for the year ended December 31, 2022.

F-18

Contractual Obligations

The following table summarizes the Company’s contractual obligations as of September 30, 2023, and the effects that such obligations are expected to have on its liquidity and cash flows in future periods (in thousands):


Maturity of Operating Leases
Years Ended December 31,	Operating Leases
2023 (excluding the nine months ended September 30, 2023)		743
2024		1,942
2025		675
2026		654
2027		326
Thereafter		—
Total payments		4,340
Less: imputed interest		(383	)
Less: foreign exchange loss		31
Total	$	3,988

In connection with the Subsidiary Sale, the Company and Ascend entered into the Transition Services Agreement whereby the Company agreed to pay Ascend a guaranteed minimum of approximately $7.9 million in respect of FTE costs. The Company will make remaining minimum guaranteed payments of $2.2 million and $3.1 million for the years ending December 31, 2023 and 2024, respectively. See Note 3, Sale of Freeline Therapeutics GmbH.

Indemnification Agreements

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.

In accordance with the Articles of Association in force on September 30, 2023, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date, and the Company has director and officer insurance that may enable it to recover a portion of any amounts paid for future potential claims.

13.

Related Party Transactions

The Company analyzed its transactions with related parties for the nine months ended September 30, 2023 and 2022, and determined it had the following material transactions.

Syncona

On March 10, 2022, the Company entered into a purchase agreement with its majority shareholder, Syncona Portfolio Limited, a subsidiary of Syncona Limited, and certain other existing shareholders providing for the issuance and sale by the Company of $26.1 million of the Company’s ADSs at a price of $1.05 per ordinary share, in a registered direct offering. The offering closed on March 15, 2022. The Company received net proceeds of approximately $24.2 million from the offering, after deducting offering expenses payable by the Company.

See Note 15, Subsequent Events, for further discussion of the definitive agreement entered into with a Syncona affiliate in November 2023.

Forcefield Therapeutics Limited

F-19

On March 21, 2023, the Company entered into an exclusive patent and know-how in-license agreement with Forcefield Therapeutics Limited ("Forcefield"), a company controlled by Syncona Limited. Under the terms of the agreement, Forcefield granted the Company an exclusive license under certain patent rights to develop and commercialize AAV gene therapies for certain cardiac conditions and a non-exclusive license to certain know-how.

The Company has committed to an upfront fee of £0.5 million or $0.6 million and may be obligated to make up to £18.3 million or $22.8 million in development and regulatory milestone payments, and pay Forcefield a mid-single-digit percentage royalty on net sales of certain royalty products on a product-by-product and country-by-country basis, until the later of (a) the expiration of the last valid licensed patent claim covering such product in such country or (b) ten years from the first commercial sale of such product sold in that country or twenty years from the date upon which the agreement was signed. The Company considers the development and regulatory milestones probable when actually achieved. During the nine months ended September 30, 2023, the Company recorded expense of $0.6 million within research and development on the Company’s unaudited condensed consolidated statements of operations related to the license agreement with Forcefield.

Syncona IP Holdco (2) Limited

See Note 4, License Revenue.

14.

Restructuring Charges

During the first quarter of 2023, the Company completed a financial and organizational assessment to increase efficiencies and reduce operating expenses. As a result of this assessment, the Company reduced its U.S. and U.K. workforce by nearly 30%. For the nine months ended September 30, 2023, the Company incurred total expenses of $1.3 million, consisting of severance and termination-related costs, which were recognized as operating expenses.

15.

Subsequent Events

On November 22, 2023, the Company entered into a definitive agreement (the “Implementation Agreement”), with Bidco 1354 Limited (“Bidco”), a wholly owned subsidiary of Syncona Portfolio Limited (collectively referred to as “Syncona”). Pursuant to the terms of the Implementation Agreement, Syncona has agreed to acquire the entire issued and to be issued share capital of the Company (the "Company Shares") for $6.50 in cash per ADS (the “Consideration”). Under the terms of the Implementation Agreement, the proposed acquisition (the "Acquisition") will be implemented by means of a scheme of arrangement to be undertaken pursuant to Part 26 of the UK Companies Act 2006 (a "Scheme"). Bidco reserves the right under the Implementation Agreement to effect the Acquisition by way of a takeover offer after consultation with the Special Committee of the Company’s Board of Directors.

The completion of the proposed Acquisition is subject to the satisfaction or waiver of certain conditions. Pursuant to the terms of the Implementation Agreement, all outstanding equity awards outstanding immediately before the Scheme is sanctioned by the High Court of Justice in England and Wales, will be accelerated in full, except that any option that has a per ADS exercise price equal to or in excess of the Consideration will be cancelled for no consideration.

The Implementation Agreement contains certain customary representations, warranties and covenants, including, among others, covenants with respect to the conduct of the Company’s business prior to completion of the Acquisition. The Implementation Agreement contains certain termination rights for both the Company and Bidco.

On November 22, 2023, the Company issued Fixed Rate Convertible Loan Notes due 2024 in aggregate principal amount of $10.0 million to Syncona (the “Convertible Notes”). On completion of certain business and Acquisition-related milestones, the Company will issue an additional $5.0 million in aggregate principal amount of Convertible Notes. The Convertible Notes bear interest at 12% per annum and interest will be capitalized monthly in arrears. Upon repayment or conversion, a premium of 10% of the principal outstanding (excluding capitalized interest) will be added to the loan balance. The Convertible Notes will mature on November 20, 2024 (the “Maturity Date”).

The Convertible Notes are convertible at the option of the holder during the period starting on the earlier to occur of May 22, 2024 and the date of termination of the Implementation Agreement and ending on the Maturity Date (the “Optional Conversion Period”). If at any time following the issuance of the Convertible Notes and prior to the Maturity Date either a Qualified Equity Financing or a Matching Right Financing (each as defined in the Secured Convertible Loan Note Certificate) occurs, the repayment amount in respect of all of the Convertible Notes will be

F-20

mandatorily converted into ADSs. During the Optional Conversion Period, the Company can redeem all or some portion of the Convertible Notes upon 30 days written notice to the holder, or such shorter period as mutually agreed with the holder.

In each case, the Convertible Notes will be converted into ADSs at the conversion price of $6.50, subject to reduction or adjustment in accordance with the terms of the Secured Convertible Loan Note Certificate (the “Conversion Price”).

Under a Security Agreement, the Company and certain of its subsidiaries provide fixed and floating charges over all of their assets (and assign certain assets) to Syncona to secure the Company’s obligations under the Convertible Notes.

F-21

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report on Form 6-K contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements are any statements other than statements of historical fact. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this report are based upon information available to us as of the date of this report and, while we believe we have a reasonable basis for each forward-looking statement contained in this report, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include, among other things, statements about:

•

the proposed Acquisition (as defined below) by Bidco 1354 Limited, a wholly owned subsidiary of Syncona Portfolio Limited (collectively referred to as "Syncona"), to acquire the Company for $6.50 in cash for each American Depositary Share, including the likelihood of obtaining shareholder approval and satisfying other conditions to complete the Acquisition;

•

the Convertible Notes (as defined below), including the use of proceeds thereof and our ability to raise additional capital with them in place, if needed

•

our estimates regarding future expenses, the period for which we expect that our current cash and cash equivalents will be sufficient to fund operations and our needs for additional funding;

•

the development of our product candidates, including statements regarding the timing and advancement of initiation, enrollment, continuation, completion and the outcome of preclinical studies or clinical trials and related preparatory work, the period during which interim data from, or the final results of, the studies or trials will become available and our research and development programs;

•

our ability to obtain and maintain regulatory approval of our product candidates in the indications for which we plan to develop them, and any related restrictions, limitations or warnings in the label of an approved drug or therapy;

•

our ability to license additional intellectual property relating to our product candidates from third parties and to comply with our existing license agreements;

•

the timing of our regulatory filings for our product candidates, along with regulatory developments in the United States, European Union and other foreign countries;

•

our plans to research, develop, manufacture and commercialize our product candidates;

•

the size and growth potential of the markets for our product candidates, if approved, and the rate and degree of market acceptance of our product candidates, including pricing and reimbursement that may be agreed with payors;

•

the impact of changes in economic, capital market and political conditions, including fluctuations in commodity prices, inflation, interest rates and foreign currency exchange rates, disruptions in global supply chains and labor markets, geopolitical risks and global hostilities, including Russia’s invasion of Ukraine and the recent conflict in Israel and Gaza;

•

our expectations regarding our ability to obtain and maintain intellectual property protection;

•

our ability to attract and retain qualified employees and key personnel;

•

our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

•

the scalability and commercial viability of our manufacturing methods and processes;

•

the success of competing therapies that are or may become available;

•

our ability to realize the anticipated benefits of any acquisitions, joint ventures or divestitures; and

•

whether we are classified as a passive foreign investment company, or PFIC, for current and future periods.

The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. The forward-looking statements contained in this report speak only as of the date of this report. You should refer to the section titled “Risk Factors” elsewhere in this report on Form 6-K and Item 3.D. “Key Information—Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2022, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this report.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) for Freeline Therapeutics Holdings plc (“us,” “we,” “our,” “Freeline,” or “the Company”), together with our unaudited condensed consolidated financial statements as of and for the nine months ended September 30, 2023 and September 30, 2022 and accompanying notes thereto, included elsewhere in this report on Form 6-K, and our audited consolidated financial statements and the related notes as of and for the fiscal year ended December 31, 2022 included in our Annual Report on Form 20-F for the year ended December 31, 2022 (the “Annual Report”), which is available through the U.S. Securities and Exchange Commission’s Electronic Data Gathering and Analysis Retrieval (“EDGAR”) system at http://www.sec.gov.

Some of the information contained in this MD&A, including, but not limited to, information with respect to our plans and strategy for our business and our expectations with respect to liquidity and capital resources, includes forward-looking statements. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, those risks and uncertainties described in the section titled “Risk Factors” elsewhere in this report on Form 6-K and Item 3.D. “Key Information—Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in our Annual Report. Our actual results could differ materially from the results described in or implied by these forward-looking statements.

Overview

We are a clinical-stage biotechnology company with the ambition of developing transformative AAV vector-mediated gene therapies. We are dedicated to improving patient lives through innovative, potential one-time treatments for chronic debilitating diseases. We use our proprietary, rationally designed AAV vector and capsid (AAVS3) along with novel promoters and transgenes to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream. Our pipeline includes a program in the clinic for Gaucher disease and research programs targeting GBA1-linked Parkinson’s disease and other novel applications for gene therapy, for which we have, through owned and in-licensed intellectual property rights, development and worldwide commercial rights. In an effort to ensure we are investing our resources in highest-value programs, we have deprioritized product candidates in Fabry disease and hemophilia B.

Since our inception in May 2015, we have devoted substantially all of our resources to conducting preclinical studies and clinical trials, organizing and staffing our company, planning our business initiatives, raising capital and establishing our intellectual property portfolio. We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations to date primarily with proceeds from the sale of our equity securities, including net proceeds from our initial public offering, or IPO, in August 2020, and subsequent issuances. Through September 30, 2023, we have received net cash proceeds of approximately $474.1 million from sales of our equity securities. In November 2023, we received $10.0 million in proceeds from the issuance of the Convertible Notes (as defined below).

As of September 30, 2023, we had unrestricted cash and cash equivalents of $29.5 million. We have incurred operating losses since inception including net losses of $26.9 million and $66.0 million for the nine months ended September 30, 2023 and 2022, respectively. As of September 30, 2023, we had an accumulated deficit of $472.3 million. We expect to continue to incur significant expenses and generate operating losses for the foreseeable future as we advance our FLT201 product candidate through clinical development, seek regulatory approval, invest further in our gene therapy platform and seek to identify new gene therapy product candidates. These conditions indicate that there is substantial doubt regarding our ability to continue as a going concern for at least 12 months from the issuance date of the accompanying unaudited condensed consolidated financial statements. See “—Liquidity and Capital Resources—Funding Requirements” below for additional information.

Recent Developments

Clinical Trial Updates

On October 4, 2023, we announced positive initial safety, tolerability and GCase enzyme activity data from the first dose cohort of the Phase 1/2 GALILEO-1 clinical trial evaluating FLT201, our adeno-associated virus gene therapy candidate in Gaucher disease type 1. On October 25, 2023, we announced new data from the trial being highlighted in an oral presentation at the European Society of Gene & Cell Therapy, or ESGCT, 30th Annual Congress held in Brussels, Belgium showing a substantial reduction of glucosylsphingosine, or lyso-Gb1, levels in the blood of the first patient treated with FLT201. A third and fourth patient were dosed in the same cohort in October and November, respectively, and several additional study patients are being scheduled for dosing.

Implementation Agreement

On November 22, 2023, we entered into a definitive agreement, or the Implementation Agreement, with Bidco 1354 Limited, or Bidco, a wholly owned subsidiary of Syncona Portfolio Limited (collectively referred to as “Syncona”) to acquire our entire issued and to be issued share capital for $6.50 in cash per ADS. Under the terms of the Implementation Agreement, the proposed acquisition, or the Acquisition, will be implemented by means of a scheme of arrangement to be undertaken by the Company pursuant to Part 26 of the UK Companies Act 2006, or a Scheme. Bidco reserves the right to effect the Acquisition by way of a takeover offer after consultation with the Special Committee of our Board of Directors. The Acquisition is subject to the approval of our minority shareholders and is expected to close in the first quarter of 2024, subject to customary closing conditions.

The completion of the proposed Acquisition is subject to the satisfaction or waiver of certain conditions, including, among other things: approval by at least 75% in value and a majority in number of the holders of issued and outstanding Company Shares present, entitled to vote and voting (in person or by proxy) at the relevant meeting. Pursuant to the terms of the Implementation Agreement, all outstanding equity awards outstanding immediately before the Scheme is sanctioned by the High Court of Justice in England and Wales will be accelerated in full, except that any option that has a per ADS exercise price equal to or in excess of the Consideration will be cancelled for no consideration.

The foregoing description of the Implementation Agreement is not complete and is subject to and qualified in its entirety by reference to the copy of the Implementation Agreement attached as Exhibit 99.1 to our report on Form 6-K filed on November 22, 2023.

Convertible Notes

On November 22, 2023, we issued $10.0 million in aggregate principal amount of Convertible Notes due November 20, 2024, or the Maturity Date, to Syncona, subject to earlier conversion or repayment. Upon completion of certain business and Acquisition-related milestones, we will issue an additional $5.0 million in aggregate principal amount of Convertible Notes.

The Convertible Notes are governed by a Secured Convertible Loan Note Certificate, dated November 22, 2023, and are secured pursuant to a Security Agreement dated November 22, 2023, granted by the Company and certain of its subsidiaries.

The Convertible Notes will bear interest at a rate of 12% per annum and interest will be capitalized monthly in arrears. Upon repayment or conversion, a premium of 10% of the principal outstanding (excluding capitalized interest) will be added to the loan balance.

The Convertible Notes are convertible into ADSs at the option of the holder during the period starting on the earlier to occur of May 22, 2024 and the date of termination of the Implementation Agreement, ending on the Maturity Date, or the Optional Conversion Period. If at any time following the issuance of the Convertible Notes and prior to the Maturity Date, either a Qualified Equity Financing or Matching Right Financing occurs (each as defined in the Secured Convertible Loan Note Certificate), the repayment amount in respect of the Convertible Notes will be mandatorily converted into ADSs. During the Optional Conversion Period, we can redeem all or some portion of the Convertible Notes (in multiples of $0.1 million) upon 30 days written notice to the holder, or such shorter period as

mutually agreed with the holder. In each case, the Convertible Notes will be converted into ADSs at $6.50, subject to reduction or adjustment in accordance with the terms of the Convertible Notes.

The foregoing summaries of the Convertible Notes, the Secured Convertible Loan Note Certificate and the Security Agreement do not purport to be complete and are subject to, and qualified in their entirety by the full text of the Security Agreement and the Secured Convertible Loan Note Certificate, which were attached as Exhibit 99.2 and Exhibit 99.3, respectively, to our report on Form 6-K filed on November 22, 2023.

Components of Our Results of Operations

Revenue

The total revenue to date has been generated from our out-license agreement with Syncona Holdco. We have not generated any revenue from product sales and do not know when or if we will generate revenue from our product sales. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales.

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred in connection with the research and development of our product candidates. Research and development expenses consist of:

•

expenses incurred in connection with the preclinical and clinical development of our product candidates, including under agreements with clinical research organizations, or CROs, and our transition services agreement with Ascend Gene & Cell Therapies Limited, or Ascend;

•

the costs of contract manufacturing organizations, or CMOs, that manufacture drug products for use in our preclinical studies and clinical trials;

•

employee-related expenses, including salaries, related benefits, travel and non-cash share-based compensation expense for employees engaged in research and development functions;

•

costs of outside consultants engaged in research and development activities, including their fees, non-cash share-based compensation and related travel expenses;

•

costs of laboratory supplies;

•

costs related to compliance with regulatory requirements;

•

facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of research and development facilities and other operating costs; and

•

upfront, milestone and management fees for maintaining licenses under our third-party licensing agreements.

We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated financial statements as a prepaid expense or accrued research and development expenses.

Certain of our direct research and development expenses are not tracked on a program-by-program basis for our product candidates and consist primarily of external costs, such as fees paid to outside consultants, CROs and CMOs in connection with our preclinical development, manufacturing and clinical development activities. License fees and other costs incurred after a product candidate has been selected that are directly related to a product candidate are included in direct research and development expenses for that program. License fees and other costs incurred prior to designating a product candidate are included in other program expense. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately

classified. We use internal resources primarily to oversee research and discovery as well as to manage our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track their costs by program.

Research and development activities are central to our business model. Our research and development expenses may decrease in the near term as a result of the program prioritization and workforce reductions announced previously. However, product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials and related product manufacturing expenses. As a result, we expect that our research and development expenses will continue to increase over the mid- to long-term as we seek to: (i) expedite clinical development and attempt to obtain marketing approval for our product candidates; (ii) initiate additional clinical trials of our product candidates; (iii) improve the efficiency and scalability of our manufacturing processes and supply chain; (iv) continue to discover and develop additional product candidates; and (v) prepare for regulatory filings related to our product candidates. We also expect to incur additional expenses related to milestone, royalty payments and maintenance fees payable to third parties with whom we have entered into license agreements to acquire the rights related to our product candidates.

The successful development and commercialization of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with development and commercialization, including the following:

•

completing research and preclinical development of our product candidates and identifying new gene therapy product candidates and investing in our gene therapy platform;

•

establishing an appropriate safety profile with IND- and CTA-enabling studies;

•

successful patient enrollment in, and the initiation and completion of, clinical trials;

•

the timing, receipt and terms of any marketing approvals from applicable regulatory authorities and reimbursement and market access from third-party payors;

•

our ability to maintain suitable arrangements with third-party manufacturers for our product candidates, including our ability to meet CMC and other regulatory requirements relating to the manufacture of product candidates;

•

obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;

•

defending against third-party infringement, misappropriation or other violation of intellectual property rights claims;

•

significant and changing government regulation;

•

launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and

•

maintaining a continued acceptable safety profile of the product candidates following approval.

A change in the outcome of any of these variables with respect to the development of our product candidates could mean a significant change in the costs and timing associated with such development. For example, if the U.S. Food and Drug Administration, the European Medicines Agency, the U.K. Medicines and Healthcare products Regulatory Agency or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to commit significant additional financial resources and time to the completion of clinical development of that product candidate.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related benefits, non-cash share-based compensation expense, travel and other expenses incurred by personnel in executive, finance and administrative functions. These expenses include professional fees for legal, consulting, accounting and audit services and other costs associated with being a public company.

Other Income, Net

Other income, net consists primarily of realized and unrealized gains and losses from foreign currency denominated cash balances and vendor payables.

Interest Income, Net

Interest income, net consists of interest income on cash and cash equivalents held in our banking institutions.

Income Tax Expense

We are subject to corporate taxation in the United States, Ireland and the United Kingdom and through the closing of the Subsidiary Sale, in Germany. Due to the nature of our business, we have generated losses since inception and therefore have not paid corporation tax in either the United Kingdom or Ireland. Our income tax expense represents income taxes in the United States and Germany.

Unsurrendered U.K. losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to £5.0 million plus an incremental 50% of U.K. taxable profits. We had accumulated tax losses for carry forward in the United Kingdom of $310.8 million as of December 31, 2022. We have not recognized any deferred tax assets to date in relation to U.K. losses. This treatment is based on the Company incurring losses while the clinical programs are not at a commercial stage. We believe there is no reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets in the United Kingdom can be realized. We have recorded a full valuation allowance against our net deferred tax assets in the United Kingdom at each balance sheet date.

Benefit from R&D Tax Credit

As a company that carries out extensive research and development activities, we seek to benefit from the U.K. research and development tax credit cash rebate, or U.K. R&D tax credit, regimes. The amount of benefits received depends on whether we qualify for a tax credit under the Research and Development Expenditure Credit, or RDEC, program. We record the U.K. R&D tax credit benefit within other income (expense), net. The U.K. R&D tax credit is fully refundable to us and is not dependent on current or future taxable income. As a result, we have recorded the entire benefit from the U.K. R&D tax credit as a benefit, which is included in our net loss before income tax and accordingly, not reflected as part of the income tax provision. If, in the future, any U.K. R&D tax credits generated are needed to offset a corporate income tax liability in the UK, that portion would be recorded as a benefit within the income tax provision and any refundable portion not dependent on taxable income would continue to be recorded within other income (expense), net.

Under the RDEC scheme, we are able to surrender some of our trading losses that arise from qualifying research and development activities for a cash rebate of up to 10.53% (or, from April 2023, 15%) of such qualifying research and development expenditure. Qualifying expenditures largely comprise employment costs for research staff, consumables and certain internal overhead costs incurred as part of research projects for which we do not receive income. Based on criteria established by HM Revenue & Customs, or HMRC, we expect a portion of expenditures being carried out in relation to our pipeline research and development, clinical trials management and manufacturing development activities to be eligible for the RDEC regime for the nine months ended September 30, 2023 and 2022.

Results of Operations

Comparison of the Nine Months Ended September 30, 2023 and 2022

The following table summarizes our results of operations for the nine months ended September 30, 2023 and 2022 (in thousands):


	Nine Months Ended September 30,
	2023			2022			Change
License revenue	$	622		$	—		$	622
Operating expenses:
Research and development		25,508			53,561			(28,053	)
General and administrative		24,001			25,009			(1,008	)
Gain on legal settlement		(2,227	)		—			(2,227	)
Restructuring expense		1,339			—			1,339
Total operating expenses		48,621			78,570			(29,949	)
Loss from operations		(47,999	)		(78,570	)		30,571
Other income, net
Gain on sale of Freeline Therapeutics GmbH		20,279			—			20,279
Gain on lease termination		—			5,307			(5,307	)
Other income, net		39			5,451			(5,412	)
Interest income, net		338			631			(293	)
Benefit from R&D tax credit		619			1,304			(685	)
Total other income, net		21,275			12,693			8,582
Net loss before income taxes		(26,724	)		(65,877	)		39,153
Income tax expense		(209	)		(96	)		(113	)
Net loss	$	(26,933	)	$	(65,973	)	$	39,040

License Revenue

License revenue increased to $0.6 million for the nine months ended September 30, 2023, due to the execution of our out-license agreement with Syncona Holdco which included recognition of a non-refundable upfront license fee payable to us. During the nine months ended September 30, 2022, we did not recognize any license revenue.

Research and Development Expenses

The following table summarizes our research and development expenses for the nine months ended September 30, 2023 and 2022 (in thousands):


	Nine Months Ended September 30,
	2023		2022		Change
Direct research and development expenses by program:
FLT201	$	3,304	$	4,714	$	(1,410	)
FLT180a		2,422		9,050		(6,628	)
FLT190		2,178		4,828		(2,650	)
Pre-clinical and discovery		5,878		3,914		1,964
Unallocated research and development expenses:
Personnel expenses		7,583		16,126		(8,543	)
Facilities and other expenses		3,351		13,254		(9,903	)
Non-cash share-based compensation expense		792		1,675		(883	)
Total research and development expenses	$	25,508	$	53,561	$	(28,053	)

Research and development, or R&D, expenses were $25.5 million for the nine months ended September 30, 2023, a decrease of approximately $28.1 million, from $53.6 million for the nine months ended September 30, 2022. The decrease in research and development expenses was primarily attributable to the following:

•

a $1.4 million decrease in spending related to FLT201, our product candidate for the treatment of Gaucher disease Type 1, primarily related to reduced manufacturing activities in 2023;

•

a $6.6 million decrease in spending related to FLT180a, our deprioritized product candidate for the treatment of hemophilia B, primarily due to our decision to halt further development of FLT180a;

•

a $2.7 million decrease in spending related to FLT190, our deprioritized product candidate for the treatment of Fabry disease, primarily due to our decision to halt further development of FLT190;

•

a $2.0 million increase in spending related to preclinical and discovery activities, primarily related to increased external research and development costs in connection with the transition services agreement with Ascend, partially offset by cost savings associated with the sale of Freeline Therapeutics GmbH, or the Subsidiary Sale;

•

an $8.5 million decrease in personnel expenses, primarily related to a reduction of R&D and manufacturing personnel in connection with the October 2022 and April 2023 reductions in workforce and the sale of Freeline Therapeutics GmbH;

•

a $9.9 million decrease in facilities and other expenses, mainly due to a reduction in CMO capacity fees and consulting expenses; and

•

a $0.9 million decrease in non-cash share-based compensation expense, primarily due to reduced R&D personnel in connection with the October 2022 and April 2023 reductions in workforce offset by incremental expense as a result of the option repricing completed in June 2023.

We generally expect these costs to increase year over year to support our plan to advance FLT201 through clinical development and our research programs targeting GBA1-linked Parkinson's disease and other novel applications for gene therapy, although certain of these costs may decrease during the next twelve months due to our strategic prioritizations, reduced expenses due to the sale of Freeline Therapeutics GmbH and reductions in workforce.

General and Administrative Expenses

The following table summarizes our general and administrative expenses for nine months ended September 30, 2023 and 2022 (in thousands):


	Nine Months Ended September 30,
	2023		2022		Change
Personnel expenses	$	6,706	$	9,783	$	(3,077	)
Legal and professional fees		6,113		7,036		(923	)
Facilities and other expense		4,774		5,828		(1,054	)
Non-cash share-based compensation expense		2,151		2,362		(211	)
Cost related to sale of Freeline Therapeutics GmbH		2,257		—		2,257
Depositary fees in connection with ADS Ratio change		2,000		—		2,000
Total general and administrative expenses	$	24,001	$	25,009	$	(1,008	)

General and administrative, or G&A, expenses were $24.0 million for the nine months ended September 30, 2023, a decrease of $1.0 million from $25.0 million for the nine months ended September 30, 2022. The decrease in general and administrative expenses was primarily attributable to the following:

•

a $3.1 million decrease in personnel expenses, primarily as a result of the October 2022 and April 2023 reductions in workforce;

•

a $0.9 million decrease in legal and professional fees, primarily related to decreased legal and consultant fees;

•

a $1.1 million decrease in facilities and other expense resulting primarily from a decrease in directors' and officers' insurance expense due to reduced premium costs;

•

a $0.2 million decrease in non-cash share-based compensation expense, primarily as a result of reduced G&A personnel in connection with the October 2022 and April 2023 reductions in workforce offset by incremental expenses as a result of the option repricing completed in June 2023; and

•

offset by costs incurred of $2.3 million associated with the sale of Freeline Therapeutics GmbH and $2.0 million associated with the ADS depositary fees in connection with the ADS ratio change completed in May 2023.

Gain on Legal Settlement

Gain on legal settlement of $2.2 million for the nine months ended September 30, 2023, represents the net gain from the Settlement Agreement in connection with the Dedicated Manufacturing and Commercial Supply Agreement with Brammer Bio MA, LLC, or the DMCSA. We released approximately $5.1 million of discharged liabilities, which was offset by the write-off of prepaid expenses of approximately $0.6 million and a cash payment of $2.25 million. There was no gain on legal settlement during the nine months ended September 30, 2022.

Total Other Income, Net

Total other income, net was $21.3 million for the nine months ended September 30, 2023, an increase of $8.6 million, from total other income, net of $12.7 million for the nine months ended September 30, 2022, primarily due to the gain of $20.3 million on the sale of Freeline Therapeutics GmbH, offset by gains during the nine months ended September 30, 2022 of $5.2 million due to the termination of the DMCSA driven by derecognizing the right-of-use-assets and operating lease liabilities and $2.1 million due to net unrealized gains on our monetary assets and liabilities arising from the translation of cash balances that were maintained in U.S. dollars, which is different from the legal entity's functional currency (pound sterling).

Liquidity and Capital Resources

Since our inception, we have incurred significant operating losses in each period and on an aggregate basis. We have not yet commercialized any of our product candidates and we do not expect to generate revenue from sales of any product candidates for several years, if at all. We have funded our operations to date primarily with proceeds from the sale of preferred shares, ordinary shares and ADSs. Through November 28, 2023, we had received aggregate net cash proceeds of $474.1 million from sales of our equity securities and the issuance of the Convertible Notes.

On September 10, 2021, we filed a shelf registration on Form F-3 (File No. 333-259444) with the SEC, which was declared effective on September 22, 2021, or the Shelf Registration. Under the Shelf Registration, we may offer and sell up to $250.0 million of a variety of securities including ordinary shares (and ordinary shares represented by ADSs), preference shares, purchase contracts, warrants, units or any combination of such securities from time to time during the three-year period that commenced upon the Shelf Registration becoming effective.

On November 17, 2021, we entered into an Open Market Sale AgreementSM, or Sales Agreement, with Jefferies LLC, or Jefferies, pursuant to which we may issue and sell ADSs having aggregate offering sales proceeds of up to $75.0 million, from time to time, in “at-the-market” offerings pursuant to which Jefferies will act as sales agent and/or principal. During the year ended December 31, 2022, we issued ADSs representing 3,037,616 ordinary shares pursuant to the Sales Agreement, resulting in net proceeds of approximately $3.2 million. During the nine months ended September 30, 2023, we did not issue any additional ADSs pursuant to the Sales Agreement.

On March 10, 2022, we entered into a purchase agreement with our majority shareholder, Syncona Portfolio Limited, a subsidiary of Syncona Limited, and certain other existing shareholders providing for the issuance and sale of $26.1 million of our ADSs at a price of $1.05 per ordinary share in a registered direct offering. The offering closed on March 15, 2022. We received net proceeds of approximately $24.2 million from the offering, after deducting offering expenses payable by us.

On March 18, 2022, we entered into a purchase agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park, under which we may at our discretion, sell to Lincoln Park up to $35.0 million of our ADSs over a 36-month period, subject to certain daily limits, applicable prices, and conditions. In addition, under the purchase agreement, we issued ADSs representing 954,208 ordinary shares to Lincoln Park as consideration for its commitment to purchase ADSs under the purchase agreement. During the nine months ended September 30, 2023, we did not issue any additional ADSs pursuant to the purchase agreement.

On February 8, 2023, we received proceeds of approximately $25.0 million from the Subsidiary Sale, subject to purchase price adjustments and related transaction costs.

On November 22, 2023, we received proceeds of $10.0 million from the issuance of the Convertible Notes further described in Note 15, Subsequent Events, in the accompanying unaudited condensed consolidated financial statements. Upon completion of certain business and Acquisition-related milestones, we will issue an additional $5.0 million in aggregate principal of Convertible Notes.

We currently have no ongoing material commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years, other than our operating lease agreements and our Transition Services Agreement described in Note 12 to the unaudited condensed consolidated financial statements.

Cash Flows

The following table summarizes our cash flows for the nine months ended September 30, 2023 and 2022 (in thousands):


	For the Nine Months Ended September 30,
	2023			2022
Net cash used in operating activities	$	(44,392	)	$	(58,373	)
Net cash provided by (used in) investing activities		23,611			(3,117	)
Net cash provided by financing activities		32			27,435
Effect of exchange rate changes on cash, cash equivalents and restricted cash		1,292			(17,949	)
Net decrease in cash, cash equivalents and restricted cash	$	(19,457	)	$	(52,004	)

Net Cash Used in Operating Activities

Net cash used in operating activities was $44.4 million for the nine months ended September 30, 2023, a decrease of $14.0 million, from $58.4 million for the nine months ended September 30, 2022, primarily resulting from a decrease of $39.0 million in our net loss to $26.9 million from $66.0 million, offset by non-cash benefits of $18.5 million and the net cash in our operating assets and liabilities of $1.0 million. The net non-cash benefit primarily related to the gain on the sale of Freeline Therapeutics GmbH of $20.3 million and the gain on legal settlement of $2.2 million, partially offset by non-cash share-based compensation of $2.9 million and depreciation of $1.1 million.

Net Cash Provided by (Used in) Investing Activities

Net cash provided by investing activities was $23.6 million for the nine months ended September 30, 2023, an increase of $26.7 million, from $3.1 million used in investing activities for the nine months ended September 30, 2022, primarily driven by proceeds from the sale of Freeline Therapeutics GmbH.

Net Cash Provided by Financing Activities

Net cash provided by financing activities was less than $0.1 million for the nine months ended September 30, 2023. Net cash provided by financing activities was $27.4 million for the nine months ended September 30, 2022, which was related to proceeds from the issuance of ordinary shares.

Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash

The effect of exchange rate changes on cash, cash equivalents and restricted cash was $1.3 million and $(17.9) million for the nine months ended September 30, 2023 and 2022, respectively, primarily related to foreign currency gains arising from the translation of cash balances that were maintained in U.S. dollars, which is different from the legal entity’s functional currency (pound sterling). Currently, our U.S. dollar balances are held in a pound sterling functional currency legal entity and converted as required into pound sterling because the predominant cash outflows are pound sterling.

Funding Requirements

We expect our expenses to decrease in connection with our ongoing activities in the near term as a result of our program prioritization and workforce reductions. However, our expenses will increase over the mid- to long-term as we:

•

continue our development of our FLT201 product candidate, including conducting our ongoing Phase 1/2 GALILEO-1 clinical trial of FLT201 for the treatment of Gaucher disease Type 1 and any other clinical trials that may be required to obtain marketing approval;

•

conduct research and development activities with respect to our research programs targeting GBA1-linked Parkinson’s disease and other novel applications for gene therapy;

•

initiate preclinical studies for future product candidates;

•

develop the necessary processes, controls and manufacturing data to obtain marketing approval for our product candidates and to support manufacturing on a commercial scale;

•

seek regulatory approvals for any product candidates that successfully complete clinical trials;

•

hire and retain additional personnel, such as clinical operations and affairs, pharmacovigilance, quality assurance, regulatory affairs, manufacturing, distribution, legal and compliance, medical affairs, finance, general and administrative, commercial and scientific personnel.

As of September 30, 2023, we had unrestricted cash and cash equivalents of $29.5 million. On November 22, 2023, we received $10.0 million from the issuance of the Convertible Notes. However, based on our recurring losses, expectation of continuing operating losses and negative cash flows from operations in the foreseeable future, the need to raise additional capital to finance future operations, we have concluded that there is substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance date of the unaudited condensed consolidated financial statements. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes we will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

As a result, we will need substantial additional funding to advance our product candidates and support our continuing operations. If the Acquisition is not completed, we will need to obtain additional funding through private and public equity offerings, debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic collaborations or licensing arrangements. If we can achieve certain business and Acquisition-related milestones, we will issue an additional $5.0 million in aggregate principal amount of Convertible Notes. To the extent that we raise additional capital through the sale of equity, current ownership interests will be diluted. If we raise additional funds through government or third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. However, there can be no assurances that additional funding will be available at all. If we are unable to raise additional funds when needed, we will be required to reduce spending and potentially delay, limit, reduce or terminate our product research and development efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Because of the numerous risks and uncertainties associated with research and development of product candidates and programs, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:

•

the scope, progress, results and costs of drug discovery, laboratory testing, preclinical and clinical development for our current and future product candidates as well as further development of our gene therapy platform;

•

our ability to enroll clinical trials in a timely manner and to quickly resolve any delays or clinical holds that may be imposed on our development programs;

•

whether we elect to invest in and develop technology with the potential for further discovery and innovation, prioritize, delay or modify certain clinical programs, or implement any other strategic, scientific or operational changes;

•

the costs, timing and outcome of regulatory review of our product candidates; and

•

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims.

Critical Accounting Estimates

Our consolidated financial statements are prepared in accordance with the accounting principles generally accepted in the United States ("U.S. GAAP"). The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue recognition, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. There have been no changes to our critical accounting estimates since December 31, 2022.

Internal Control over Financial Reporting

We have evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Our disclosure controls and procedures are designed to ensure that the information we are required to disclose in the reports we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.

Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2023, our disclosure controls and procedures were effective.

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the period covered by this report on Form 6-K that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Emerging Growth Company Status Accounting Election

As an emerging growth company, we have elected to use the extended transition period under the JOBS Act until the earlier of the date we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

We intend to rely on certain of the other exemptions and reduced reporting requirements provided by the JOBS Act. As an emerging growth company, we are not required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b), and (ii) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis).

RISK FACTORS

Except as set forth below, there have been no material changes to the Company’s risk factors as disclosed in Item 3.D. “Key Information—Risk Factors,” in our Annual Report on Form 20-F for the fiscal year ended December 31, 2022.

We will need substantial additional funding to complete the development, obtain regulatory approval and commence commercialization of our product candidates, which may not be available on acceptable terms, if at all. Failure to obtain additional funding when required may force us to delay, limit or terminate our product development efforts or other operations.

In our unaudited condensed consolidated financial statements for the nine months ended September 30, 2023, included elsewhere in this report, we note that there is substantial doubt about our ability to continue as a going concern. In order to continue operating as a going concern, we will need to raise additional capital. We will need to obtain this additional funding through private and public equity offerings, debt financings, government or other third-party funding, strategic collaborations or licensing arrangements. Additional financing may not be available when we need it or may not be available on terms that are favorable to us. Adverse conditions in the industry or the domestic and global financial markets, including due to interest rate increases or inflation, could increase our costs for additional financing. If we are unable to raise the requisite funds on a timely basis, we will be required to reduce spending and potentially delay, limit, reduce or terminate our product research and development efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves, any of which could harm our business and potentially cause us to discontinue operations.

As of September 30, 2023, we had approximately $29.5 million in unrestricted cash and cash equivalents. On November 22, 2023, we received $10.0 million from the issuance of the Convertible Notes. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, initiate further clinical trials of and seek marketing approval for our product candidates. In addition, if we obtain marketing approval for our product candidates, we expect to incur significant expenses related to product sales, medical affairs, marketing, manufacturing and distribution. Furthermore, in the event the Acquisition is not completed, we would expect to continue to incur additional costs associated with operating as a public company. Our future capital requirements will depend on many factors, including:

•

the scope, progress, results and costs of drug discovery, laboratory testing, preclinical and clinical development for our current and future product candidates, as well as further development of our gene therapy platform;

•

our ability to enroll clinical trials in a timely manner and to quickly resolve any delays or clinical holds that may be imposed on our development programs;

•

the costs, timing and outcome of regulatory review of our product candidates;

•

our ability to establish and maintain collaborations and license agreements on favorable terms, if at all;

•

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;

•

the extent to which we acquire technologies;

•

the costs, timing and outcome of potential future commercialization activities, including manufacturing, marketing, sales and distribution for any product candidates for which we receive marketing approval;

•

the sales price and availability of adequate third-party coverage and reimbursement for our product candidates, if and when approved;

•

the costs of operating as a public company in the event the Acquisition is not completed; and

•

the cost of using contract manufacturers.

Even if we are able to obtain additional funding to alleviate the substantial doubt about our ability to continue operating as a going concern in the near term, developing product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our product revenues, if any, will be derived from or based on sales of product candidates that may not be commercially available for many years, if at all. Accordingly, we will need to continue to rely on substantial additional financing to achieve our long-term business objectives. Adequate additional financing may not be available to us on acceptable terms, if at all.

The proposed Acquisition may be delayed or not occur at all for a variety of reasons, some of which are outside of the parties’ control, and if these conditions are not satisfied, the Implementation Agreement may be terminated and the Acquisition may not be completed.

On November 22, 2023, we entered into an Implementation Agreement (the “Implementation Agreement”), with Bidco 1354 Limited (“Bidco”), a wholly owned subsidiary of our majority shareholder Syncona Portfolio Limited (collectively referred to as “Syncona”). Pursuant to the terms of the Implementation Agreement, Syncona has agreed to acquire the entire issued and to be issued share capital of our company (the “Company Shares”) for $6.50 in cash per ADS, excluding any treasury shares, any Company Shares held by Bidco or its affiliates, and certain pre-initial public offering equity awards forfeited upon the termination of the holder’s employment (the “Scheme Shares”). Under the terms of the Implementation Agreement, the proposed Acquisition would be implemented by means of a scheme of arrangement to be undertaken by us pursuant to Part 26 of the UK Companies Act 2006 (a “Scheme”). Bidco reserved the right under the Implementation Agreement to effect the proposed Acquisition by way of a takeover offer in accordance with section 974 of the UK Companies Act 2006 after consultation with a special committee of our independent directors (the “Special Committee”).

The completion of the proposed Acquisition is subject to the satisfaction or waiver of certain conditions, including, among other things: (1) the absence of any law or order by any governmental authority enjoining, preventing, restraining, prohibiting or otherwise making illegal the proposed acquisition; (2) the accuracy of our representations and warranties under the Implementation Agreement (subject to a material adverse effect standard in certain cases); (3) the absence of a Company material adverse effect; and (4) our compliance with our obligations under the Implementation Agreement. The proposed Acquisition is also subject to, among other things: approval by at least 75% in value and a majority in number of the holders of Scheme Shares (the “Company Shareholders”), present, entitled to vote and voting (in person or by proxy) at the meeting to be convened by order of the High Court of Justice in England and Wales (the “Court”) in order for the Company Shareholders to consider, and if thought fit, to approve, the Scheme (the “Court Meeting”); the passing of all resolutions necessary to approve and implement the Scheme by the requisite majority at the general meeting to be convened for Company Shareholders to consider, and if thought fit approve, certain matters in connection with the Scheme and the proposed Acquisition; and the sanctioning of the Scheme by the Court. Syncona will not be entitled to vote at the Court Meeting.

In addition, if the Scheme does not become effective by 11:59 p.m. on May 22, 2024, the Acquisition will lapse and either party will be entitled to terminate the Implementation Agreement. The Implementation Agreement also contains certain other termination rights for each of us and Syncona. Failure to complete the Acquisition could adversely affect our business and the market price of our ADSs in a number of ways, including:

•

The market price of our ADSs may decline to the extent that the current market price reflects an assumption that the Acquisition will be consummated;

•

We will need substantial additional funding to continue operations and potentially repay the Convertible Loan Notes, which may not be available on acceptable terms, if at all;

•

We have incurred, and will continue to incur, significant expenses for professional services in connection with the Acquisition for which we will have received little or no benefit if the Acquisition is not consummated;

•

A failed Acquisition may result in negative publicity and/or give a negative impression of us in the investment community, with our customers and our other stakeholders; and

•

Syncona will have the right to convert its Convertible Loan Notes into ADSs during the Optional Conversion Period.

Efforts to complete the Acquisition could disrupt our relationships with third parties and employees, divert management’s attention, or result in negative publicity or legal proceedings, any of which could negatively impact our operating results and ongoing business.

We have expended, and continue to expend, significant management time and resources in an effort to complete the Acquisition, which may have a negative impact on our ongoing business and operations. Uncertainty regarding the outcome of the Acquisition and our future could disrupt our business relationships with our existing and potential suppliers, vendors, distributors, landlords and other business partners, who may attempt to negotiate changes in existing business relationships or consider entering into business relationships with parties other than us. Uncertainty regarding the outcome of the Acquisition could also adversely affect our ability to recruit and retain key personnel and other employees. The pendency of the Acquisition may also result in negative publicity and a negative impression of us in the financial markets, and may lead to litigation against us and our directors and officers. Such litigation would be distracting to management and, may, in the future, require us to incur significant costs. Such litigation could result in the Acquisition being delayed and/or enjoined by a court of competent jurisdiction, which could prevent the Acquisition from becoming effective. The occurrence of any of these events individually or in combination could have a material and adverse effect on our business, financial condition and results of operations.

While the Implementation Agreement is in effect, we are subject to restrictions on our business activities.

While the Implementation Agreement is in effect, we are subject to certain restrictions on our business activities and must generally operate our business in the ordinary course. These restrictions could prevent us from pursuing attractive business opportunities that may arise prior to the consummation of the Acquisition and may, as a result, materially and adversely affect our business, financial condition and results of operations. Although we may be able to pursue such activities with Syncona’s consent, Syncona may not be willing to provide its consent for us to do so.

The issuance of our Convertible Loan Notes could cause dilution, which could cause the market price of our ADSs to decline.

On November 22, 2023, we issued $10,000,000 in aggregate principal amount of Fixed Rate Convertible Loan Notes due 2024 (the “Convertible Loan Notes”) to Syncona pursuant to the Secured Convertible Loan Note Certificate dated November 22, 2023, executed by us (the “Secured Convertible Loan Note Certificate”). On completion of certain business and Acquisition-related milestones, we will issue an additional $5,000,000 in aggregate principal amount of Convertible Loan Notes. The Convertible Loan Notes will bear interest on a daily basis at a rate of 12% per annum. Interest on the Convertible Loan Notes will be capitalized monthly in arrears. Upon repayment or conversion, a premium of 10% of the principal outstanding (excluding capitalized interest) will be added to the loan balance. It is expected that the Convertible Loan Notes will mature on November 20, 2024 (the “Maturity Date”), subject to earlier conversion or repayment.

The Convertible Loan Notes are convertible at the option of Syncona during the period starting on the earlier to occur of May 22, 2024 and the date of termination of the Implementation Agreement and ending on the Maturity Date (the "Optional Conversion Period") into ADSs on and subject to certain conditions. If at any time following the issuance of the Convertible Loan Notes and prior to the Maturity Date either a Qualified Equity Financing or a Matching Right Financing (each as defined in the Secured Convertible Loan Note Certificate) shall occur, the Repayment Amount (as defined in the Secured Convertible Loan Note Certificate) in respect of all of the Convertible Loan Notes shall be mandatorily converted into ADSs. In each case, the Convertible Loan Notes will be converted

into ADSs at the conversion price of $6.50, subject to reduction or adjustment in accordance with the terms of the Secured Convertible Loan Note Certificate.

In the event the Implementation Agreement is terminated or the Acquisition has not been completed by May 22, 2024, the Optional Conversion Period will begin. We have no control over whether Syncona will exercise its right to convert its Convertible Loan Notes during the Optional Conversion Period. Additionally, in the event a Qualified Equity Financing or a Matching Right Financing occur, the Repayment Amount would be mandatorily converted into ADSs. The conversion of some or all of the Convertible Loan Notes at the conversion price of $6.50 or at a potentially reduced conversion price would significantly dilute the ownership interests of existing holders of our ADSs. Any sales in the public market of our ADSs issuable upon such conversion of the Convertible Loan Notes could adversely affect prevailing market prices of our ADSs. Also, the market’s expectation that conversions may occur could depress the market price of our ADSs even in the absence of actual conversions. The existence and potentially dilutive impact of the Convertible Loan Notes may also prevent us from obtaining additional financing in the future on favorable terms, or at all.

Failure to remain in compliance with the terms of the Convertible Loan Notes could, among other things, adversely affect our business and financial condition in the future, our ability to obtain additional financing, the ownership interest of our existing shareholders, the assets of the Company and our subsidiaries and the market price of our ADSs.

The Convertible Loan Notes provide for customary events of default, including, but not limited to, our failing to make timely payments relating to amounts due under the Convertible Loan Notes, defaulting on other indebtedness of the Company or its subsidiaries, certain insolvency events, cessation of listing or suspension of trading of our ADSs on the Nasdaq, a Company material adverse effect or enforcement of any security created or assumed by the Company or any of its subsidiaries. In the event the Acquisition is not completed, such provisions and other provisions included in the Convertible Loan Notes may restrict or impair our ability to obtain additional financing in the future. Our ability to remain in compliance with the provisions of the Convertible Loan Notes and, in the event the Acquisition is not completed and the Convertible Loan Notes are never converted into ADSs, to repay the principal, interest and premium on the Maturity Date or to refinance the Convertible Loan Notes depends on, among other things, our operating performance, competitive developments, financial market conditions, and the stock exchange listing of our ADSs, which are subject to economic, financial, business, competitive, regulatory and other factors beyond our control. Accordingly, our cash and cash equivalents may not be sufficient to allow us to repay the principal, interest and premium on the Maturity Date. We may be required to adopt one or more alternatives, such as selling assets or obtaining additional equity capital on terms that may be onerous or highly dilutive.

Pursuant to the Security Agreement, the Company and certain of its subsidiaries have granted fixed and floating charges over all of their assets (and assign certain assets) to Syncona to secure the Company’s obligations under the Convertible Loan Notes. If the Company breaches its obligations under the Convertible Loan Notes, subject in various cases to certain cure rights, Syncona would be entitled to enforce the Security Agreement and dispose and liquidate some or all of the assets secured by the Security Agreement in order to discharge the amount owed to Syncona under the Convertible Loan Notes, which could harm our business, financial condition and results of operations and the market price of our ADSs, and could require us to curtail or cease operations.

EXHIBIT INDEX


Exhibit		Description

101		The following materials formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Unaudited Condensed Consolidated Balance Sheets as of September 30, 2023 and 2022, (ii) Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the nine month periods ended September 30, 2023 and 2022 and, (iii) Unaudited Condensed Consolidated Statements of Cash Flows for the nine month periods ended September 30, 2023 and 2022 and (iv) Notes to Unaudited Condensed Consolidated Financial Statements.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.


FREELINE THERAPEUTICS HOLDINGS PLC

By:	/s/ Michael J. Parini
	Name:	Michael J. Parini
	Title:	Chief Executive Officer


By:	/s/ Paul M. Schneider
	Name:	Paul M. Schneider
	Title:	Chief Financial Officer

Date: December 1, 2023

Exhibit 99.1

Freeline Reports Second Quarter 2023 Financial Results and Business Highlights

Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical data in third quarter of 2023

Extending impact of its novel GCase variant with research program for GBA1-linked Parkinson’s disease

Management to host conference call at 8:00 a.m. ET today

LONDON, August 15, 2023 – Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported financial results for the second quarter of 2023 and provided a business update.

“FLT201 is a potential first- and best-in-class gene therapy for Gaucher disease Type 1, the most common type of the disease,” said Michael Parini, Chief Executive Officer of Freeline. “Advancing the program is our top strategic priority, and we are extremely pleased with our recent progress and the momentum in the trial. The completion of dosing in the first cohort of our GALILEO-1 trial of FLT201 represents a significant milestone for the program, for Freeline and for the Gaucher community. We believe FLT201 has the opportunity to dramatically reduce the disease and treatment burden for people with Gaucher disease. We look forward to reporting initial clinical data in the third quarter of this year.”

“In the second quarter, we also unveiled our lead research program in GBA1-linked Parkinson’s disease, which leverages the same longer-acting GCase variant as FLT201,” Parini continued. “As in Gaucher disease, GBA1 mutations lead to a deficiency of the GCase enzyme and an accumulation of pathological substrates. Approximately 200,000 people with Parkinson’s disease in the US, UK and four major European markets have GBA1 mutations, making it the most common genetic risk factor for the disease. Our GBA1-linked Parkinson’s disease program is a natural extension of our work in Gaucher and an opportunity to extend the therapeutic potential of our longer-acting GCase variant into a genetically defined patient population with a serious unmet need.”

Anticipated Clinical Data for FLT201

•

Initial clinical data, with a focus on assessments of safety and enzyme activity, from the first cohort of the GALILEO-1 Phase 1/2 trial of FLT201 is expected in the third quarter of 2023. GALILEO-1 is a first-in-human, international, multicenter Phase 1/2 dose-finding study assessing the safety, tolerability, and efficacy of a single intravenous dose of FLT201, the company’s adeno-associated virus (AAV) gene therapy candidate for Gaucher disease Type 1.

Recent Corporate Highlights

•

Today, Freeline announced the dosing of the second patient in its GALILEO-1 trial of FLT201, marking the completion of dosing in the first cohort.

•

In June, the company announced the dosing of the first patient in its GALILEO-1 trial.

•

Also in June, Freeline unveiled its research program in GBA1-linked Parkinson’s disease. The program builds on its work in Gaucher disease, leveraging the same rationally engineered longer-acting GCase variant as used in FLT201 to develop a gene therapy candidate for a subset of Parkinson’s disease patients with mutations in the GBA1 gene. In preclinical studies, Freeline’s GCase variant has demonstrated at least 20-fold greater activity levels compared to wildtype enzyme in various cell lines, including brain epithelial and neuroblastoma cells.

Q2 2023 Financial Results

•

Cash Position: As of June 30, 2023, unrestricted cash and cash equivalents were $38.8 million, compared to $55.4 million as of March 31, 2023. Freeline expects its current level of cash and cash equivalents will enable the company to fund its planned operations into the second quarter of 2024.

•

Research and Development (R&D) Expenses: R&D expenses were $19.7 million for the six months ended June 30, 2023, as compared to $38.8 million for the same period in 2022. The $19.1 million decrease was primarily attributable to a decrease in expenditures related to the company’s deprioritized FLT180a and FLT190 programs, including CMC costs and capacity fees, and reduced headcount-related costs, including share-based compensation expense.

•

General and Administrative (G&A) Expenses: G&A expenses for the six months ended June 30, 2023, were $17.6 million, as compared to $16.3 million for the same period in 2022. The increase of $1.3 million was driven by $2.2 million in costs associated with the sale of Freeline Therapeutics GmbH and $2.0 million associated with the ADS depositary fees in connection with the ADS ratio change. These increases were offset by reduced G&A headcount-related costs, including share-based compensation expense.

•

Gain on Settlement Agreement: The company recorded a gain of $2.2 million due to the mutual release and settlement agreement with Brammer Bio MA, LLC announced in May, which included the release of approximately $4.5 million of discharged net liabilities offset by a settlement payment of $2.3 million.

•

Net Loss: Net loss was $14.8 million, or $0.23 per ordinary share, for the six months ended June 30, 2023, as compared to a net loss of $51.1 million, or $0.95 per ordinary share, in the same period in 2022.

About Freeline Therapeutics

Freeline is a clinical-stage biotechnology company focused on developing transformative gene therapies for chronic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into a patient’s bloodstream. The company is currently advancing FLT201, a highly differentiated gene therapy candidate that delivers a novel transgene, in a Phase 1/2 clinical trial in people with Gaucher disease type 1. Freeline has additional programs in research, including one focused on GBA1-linked Parkinson’s disease that leverages the same novel transgene as FLT201. Freeline is headquartered in the UK and has operations in the United States. For more information, visit www.freeline.life or connect with Freeline on LinkedIn and Twitter.

Forward-Looking Statements

This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express opinions, expectations, beliefs, plans, objectives, assumptions or projections of Freeline Therapeutics Holdings plc (the “Company”) regarding future events or results, in contrast with statements that reflect historical facts. Examples include, among other topics, statements regarding the potential of FLT201 to be a first- and best-in-class gene therapy for Gaucher disease; the opportunity to extend the therapeutic potential of the Company’s longer-acting GCase variant into a genetically defined patient population with a serious unmet need; the Company’s expectations regarding its use of cash and cash runway; and the timing of data readouts from the Company’s GALILEO-1 Phase 1/2 clinical trial. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks and uncertainties, including the Company’s recurring losses from operations; the uncertainties inherent in research and development of the Company’s product candidates as well as risks associated with preclinical and clinical data, including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the Company’s ability to design and implement successful clinical trials for its product candidates; whether the Company’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements for the Company’s expected timeline in light of management’s substantial doubt regarding the Company’s ability to continue as a going concern for at least 12 months from the issuance date of this press release; the Company’s failure to demonstrate the safety and efficacy of its product candidates; the Company’s ability to enroll patients in clinical trials for its product candidates; the possibility that one or more of the Company’s product candidates may cause serious adverse, undesirable or unacceptable side effects or have other properties that could delay or prevent their regulatory approval or limit their commercial potential; the Company’s ability to obtain and maintain regulatory approval of its product candidates; the Company’s limited manufacturing experience, which could result in delays in the development of its product candidates; and the Company’s ability to identify or discover additional product candidates, or failure to capitalize on programs or product candidates. A further list and description of risks, uncertainties, and other matters can be found in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2022, and in subsequent reports on Form 6-K, in each case including in the sections thereof captioned “Cautionary Statement Regarding Forward-Looking Statements” and “Item 3.D. Risk factors.” Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please reference the Company’s reports and documents filed with the U.S. Securities and Exchange Commission (the “SEC”). You may review these documents by visiting EDGAR on the SEC website at www.sec.gov.

Unaudited Condensed Consolidated Statements of Operations

(in thousands of U.S. dollars, except per share data)


	For the Six Months Ended June 30,
	2023			2022
License revenue	$	617		$	—
OPERATING EXPENSES:
Research and development		19,720			38,785
General and administrative		17,581			16,278
Gain on legal settlement		(2,227	)		—
Restructuring expense		1,276			—
Total operating expenses		36,350			55,063
LOSS FROM OPERATIONS:		(35,733	)		(55,063	)
OTHER INCOME (EXPENSE) NET:
Gain on sale of Freeline Therapeutics GmbH		20,279			—
Other (expense) income, net		73			2,973
Interest income, net		240			335
Benefit from R&D tax credit		464			721
Total other income, net		21,056			4,029
Net loss before income taxes		(14,677	)		(51,034	)
Income tax expense		(168	)		(46	)
Net loss	$	(14,845	)	$	(51,080	)
Net loss per share attributable to ordinary shareholders—basic and diluted	$	(0.23	)	$	(0.95	)
Weighted average ordinary shares outstanding—basic and diluted		65,140,334			53,587,167

Unaudited Condensed Consolidated Balance Sheets

(in thousands of U.S. Dollars)


	June 30,			December 31,
	2023			2022
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	38,797		$	47,279
License receivable		631			—
Prepaid expenses and other current assets		6,385			6,235
Assets held for sale		—			14,113
Total current assets		45,813			67,627
NON-CURRENT ASSETS:
Property and equipment, net		9,284			9,007
Operating lease right of use assets		4,792			6,014
Other non-current assets		2,764			3,993
Total assets	$	62,653		$	86,641
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable	$	6,875		$	10,058
Accrued expenses and other current liabilities		8,963			7,908
Operating lease liabilities, current		2,842			2,663
Liabilities related to assets held for sale		—			10,337
Total current liabilities		18,680			30,966
NON-CURRENT LIABILITIES:
Operating lease liabilities, non-current		1,957			3,261
Total liabilities		20,637			34,227
SHAREHOLDERS’ EQUITY:
Deferred shares		137			137
Additional paid-in capital		502,861			500,781
Accumulated other comprehensive (loss) gain		(784	)		(3,151	)
Accumulated deficit		(460,198	)		(445,353	)
Total shareholders’ equity		42,016			52,414
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	62,653			$ 86,641

Media and Investor Contact:
Naomi Aoki

naomi.aoki@freeline.life
Senior Vice President, Head of Investor Relations & Communications
+ 1 617 283 4298

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2023
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Registrant Name	Freeline Therapeutics Holdings plc
Entity Central Index Key	0001810031
Current Fiscal Year End Date	--12-31
Entity File Number	001-39431
Entity Address, Address Line One	Sycamore House
Entity Address, Address Line Two	Gunnels Wood Road
Entity Address, City or Town	Stevenage
Entity Address Postal Zip Code	Hertfordshire SG1 2BP
Entity Address, Country	GB

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 29,452	$ 47,279
Prepaid expenses and other current assets	4,544	6,235
Assets held for sale		14,113
Total current assets	33,996	67,627
Non-current assets:
Property and equipment, net	8,625	9,007
Operating lease right of use assets	3,926	6,014
Other non-current assets	2,672	3,993
Total assets	49,219	86,641
Current Liabilities:
Accounts payable	7,778	10,058
Accrued expenses and other current liabilities	7,413	7,908
Operating lease liabilities, current	2,286	2,663
Liabilities related to assets held for sale		10,337
Total current liabilities	17,477	30,966
Non-current liabilities:
Operating lease liabilities, non-current	1,702	3,261
Total liabilities	19,179	34,227
Commitments and contingencies (Note 12)
Shareholders' equity:
Additional paid-in capital	503,756	500,781
Accumulated other comprehensive loss	(1,567)	(3,151)
Accumulated deficit	(472,286)	(445,353)
Total shareholders’ equity	30,040	52,414
Total liabilities and shareholders' equity	49,219	86,641
Deferred Shares One
Shareholders' equity:
Deferred shares, value	$ 137	$ 137

Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - £ / shares	Sep. 30, 2023	Dec. 31, 2022
Ordinary shares, par value	£ 0.00001	£ 0.00001
Ordinary shares, authorized	400,000,000	400,000,000
Ordinary shares, issued	65,369,206	65,113,575
Ordinary shares, outstanding	65,369,206	65,113,575
Deferred Shares
Deferred shares, par value	£ 0.00001	£ 0.00001
Deferred shares, authorized	37,613	24,812
Deferred shares, issued	37,613	24,812
Deferred shares, outstanding	37,613	24,812
Deferred Shares One
Deferred shares, par value	£ 100,000	£ 100,000
Deferred shares, authorized	1	1
Deferred shares, issued	1	1
Deferred shares, outstanding	1	1

Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
License revenue	$ 622
Revenue, Product and Service [Extensible Enumeration]	License
Operating expenses:
Research and development expenses	$ 25,508	$ 53,561
General and administrative	24,001	25,009
Gain on legal settlement	(2,227)
Restructuring charges	1,339
Total operating expenses	48,621	78,570
Loss from operations:	(47,999)	(78,570)
Other income, net:
Gain on sale of Freeline Therapeutics GmbH	20,279
Gain on lease termination		5,307
Other income, net	39	5,451
Interest income, net	338	631
Benefit from R&D tax credit	619	1,304
Total other income (expense), net	21,275	12,693
Net loss before income taxes	(26,724)	(65,877)
Income tax expense	(209)	(96)
Net loss	$ (26,933)	$ (65,973)
Net loss per share attributable to ordinary shareholders-basic	$ (0.41)	$ (1.15)
Net loss per share attributable to ordinary shareholders-diluted	$ (0.41)	$ (1.15)
Weighted average number of ordinary shares outstanding - Basic	65,217,110	57,384,985
Weighted-average number of ordinary shares outstanding - Diluted	65,217,110	57,384,985

Unaudited Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (26,933)	$ (65,973)
Other comprehensive loss:
Foreign currency translation adjustment	1,429	(18,324)
Comprehensive loss	$ (25,504)	$ (84,297)

Unaudited Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Ordinary GBP 0.00001 Par Value	Deferred Shares GBP 0.00001 Par Value	Deferred Shares GBP 100,000 Par Value	Additional Paid-in Capital	Accumulated other comprehensive gain (loss)	Accumulated Deficit
Balance at Dec. 31, 2021	$ 120,441			$ 137	$ 467,213	$ 9,472	$ (356,381)
Balance, Shares at Dec. 31, 2021		35,854,591	112,077	1
Shares issued under employee share purchase plan	110				110
Shares issued under employee share purchase plan, Shares		149,254
Vesting of restricted share units, Shares		34,063
Forfeiture of ordinary shares, Shares		(5,477)	5,477
Issuance of ordinary shares, net of issuance cost of $2,600	28,291				28,291
Issuance of ordinary shares, net of issuance cost of $2,600, Shares		28,848,968
Cancellation of deferred shares, Shares			(93,451)
Non-cash share-based compensation	4,037				4,037
Unrealized loss on foreign currency translation	(18,324)					(18,324)
Net loss	(65,973)						(65,973)
Balance at Sep. 30, 2022	68,582			$ 137	499,651	(8,852)	(422,354)
Balance, Shares at Sep. 30, 2022		64,881,399	24,103	1
Balance at Dec. 31, 2021	120,441			$ 137	467,213	9,472	(356,381)
Balance, Shares at Dec. 31, 2021		35,854,591	112,077	1
Balance at Dec. 31, 2022	52,414			$ 137	500,781	(3,151)	(445,353)
Balance, Shares at Dec. 31, 2022		65,113,575	24,812	1
Shares issued under employee share purchase plan	32				32
Shares issued under employee share purchase plan, Shares		217,755
Vesting of restricted share units, Shares		50,677
Forfeiture of ordinary shares, Shares		(12,801)	12,801
Non-cash share-based compensation	2,943				2,943
Unrealized loss on foreign currency translation	1,429					1,429
Release of cumulative foreign currency translation adjustment, upon sale of Freeline Therapeutics GmbH	155					155
Net loss	(26,933)						(26,933)
Balance at Sep. 30, 2023	$ 30,040			$ 137	$ 503,756	$ (1,567)	$ (472,286)
Balance, Shares at Sep. 30, 2023		65,369,206	37,613	1

Unaudited Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2023 £ / shares	Sep. 30, 2022 £ / shares
Ordinary shares, par value		£ 0.00001	£ 0.00001
Issuance of ordinary shares, issuance cost \| $	$ 2,600
Deferred Shares GBP 0.00001 Par Value
Deferred shares, par value		0.00001	0.00001
Deferred Shares GBP 100,000 Par Value
Deferred shares, par value		£ 100,000	£ 100,000

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (26,933)	$ (65,973)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	1,139	1,426
Non-cash share-based compensation expense	2,943	4,037
(Gain) loss on disposal of property and equipment	(47)	238
Gain on sale of Freeline Therapeutics GmbH	(20,279)
Gain on legal settlement	(2,227)
Gain on lease termination		(5,307)
Changes in components of operating assets and liabilities
Prepaids and other current assets	916	(1,917)
Other non-current assets		(162)
Operating lease right of use assets	2,180	46,594
Accounts payable	518	5,217
Accrued expenses and other current liabilities	(440)	(4,110)
Operating lease liabilities, net	(2,162)	(38,416)
Net cash used in operating activities	(44,392)	(58,373)
Cash flows from investing activities:
Purchase of property and equipment	(654)	(3,117)
Proceeds from the sale of equipment	62
Proceeds from the sale of Freeline Therapeutics GmbH, net of cash transferred with sale of $1,015	24,203
Net cash provided by (used in) investing activities	23,611	(3,117)
Cash flows from financing activities:
Proceeds from issuance of ordinary shares		27,328
Proceeds from employee share purchase plan	32	107
Net cash provided by financing activities	32	27,435
Effect of exchange rate changes on cash, cash equivalents and restricted cash	1,292	(17,949)
Net decrease in cash, cash equivalents and restricted cash	(19,457)	(52,004)
Cash, cash equivalents and restricted cash
Beginning of period	48,909	119,063	$ 119,063
End of period	29,452	67,059	48,909
Supplemental disclosure of non-cash flow information:
Commitment shares issued to Lincoln Park Capital Fund, LLC		963
Property and equipment unpaid and accrued	35	1,221
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	29,452	65,848	47,279
Long-term restricted cash		1,211
Total cash, cash equivalents and restricted cash	$ 29,452	$ 67,059	$ 48,909

Unaudited Condensed Consolidated Statements of Cash Flows (Parenthetical) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Statement of Cash Flows [Abstract]
Cash transferred from sale of Freeline Therapeutics GmbH	$ 1,015

Nature of the Business	9 Months Ended
Nature of the Business	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business	1. Nature of the Business Freeline Therapeutics Holdings plc (the “Company”) is a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated gene therapies for patients suffering from chronic debilitating diseases. The Company is headquartered in the United Kingdom (“U.K.”) and has operations in the United States (“U.S.”). The Company is a public limited company incorporated pursuant to the laws of England and Wales. Going Concern In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, the ability to secure additional capital to fund operations, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with government regulations. Product candidates currently under development require significant additional research and development efforts, including clinical testing and regulatory approval, prior to any commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from any product sales. The Company has funded its operations primarily with proceeds from the sale of its equity securities. As of September 30, 2023, the Company had unrestricted cash and cash equivalents of $29.5 million. The Company has incurred recurring losses since its inception including net losses of $26.9 million and $66.0 million for the nine months ended September 30, 2023 and 2022, respectively. In addition, the Company had an accumulated deficit of $472.3 million as of September 30, 2023. Net cash used in operating and investing activities was $20.8 million for the nine months ended September 30, 2023. The Company expects to continue to incur significant expenses and generate operating losses for the foreseeable future. These conditions indicate that there is substantial doubt regarding the Company's ability to continue as a going concern for at least 12 months from the issuance date of these unaudited condensed consolidated financial statements. As a result, the Company will need additional funding to support its continuing operations. There can be no assurances, however, that additional funding will be available on favorable terms, or at all. If adequate funds are not available, the Company will be required to further reduce headcount as well as spending and potentially delay, limit, reduce or terminate its product research and development efforts in order to enable it to meet its obligations as they fall due for the foreseeable future. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements as of and for the year ended December 31, 2022 in the Annual Report on Form 20-F. There have been no material changes to the significant accounting policies during the nine months ended September 30, 2023, except as described below. License Revenue The Company accounts for its revenues pursuant to the provisions of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The Company has no products approved for commercial sale and has not generated any revenue from commercial product sales. The revenue earned to date has been generated solely from an out-licensing agreement. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the arrangement within the scope of ASC 606, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. License Fees and Multiple Element Arrangements If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license at such time as the license is transferred to the licensee and the licensee is able to use, and benefit from, the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Appropriate methods of measuring progress include output methods and input methods. In determining the appropriate method for measuring progress, the Company considers the nature of service that the Company promises to transfer to the customer. When the Company decides on a method of measurement, the Company will apply that single method of measuring progress for each performance obligation satisfied over time and will apply that method consistently to similar performance obligations and in similar circumstances. Contingent Research Milestone Payments ASC 606 constrains the amount of variable consideration included in the transaction price in that either all, or a portion, of an amount of variable consideration should be included in the transaction price. The variable consideration amount should be included only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The assessment of whether variable consideration should be constrained is largely a qualitative one that has two elements: the likelihood of a change in estimate, and the magnitude thereof. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized is not significant. If the consideration in a contract includes a variable amount, the Company will estimate the amount of consideration in exchange for transfer of promised goods or services. The consideration also can vary if the Company’s entitlement to the consideration is contingent on the occurrence or non-occurrence of a future event. The Company considers contingent research milestone payments to fall under the scope of variable consideration, which should be estimated for revenue recognition purposes at the inception of the contract and reassessed ongoing at the end of each reporting period. If the Company determines that variable consideration should be constrained, the variable consideration is not included as part of the transaction price. This includes an assessment of the probability that all or some of the milestone revenue could be reversed when the uncertainty around whether or not the achievement of each milestone is resolved, and the amount of reversal could be significant. The Company considers all relevant factors in accordance with U.S. GAAP when assessing whether variable consideration should be constrained and no one factor is determinative. Royalty Revenue For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and in which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

Sale of Freeline Therapeutics GmbH

9 Months Ended

Sep. 30, 2023

Discontinued Operations and Disposal Groups [Abstract]

Sale of Freeline Therapeutics GmbH

The table below sets forth the book value of the Freeline Therapeutics GmbH assets and liabilities sold along with the calculation of the gain on sale based on the cash consideration received.


	(in thousands)
Book value of assets sold
Cash and cash equivalents	$	1,015
Prepaid expenses and other current assets		414
Property and equipment, net		5,470
Operating lease right of use assets		8,455
Other non-current assets		3
Amounts attributable to assets sold		15,357
Book value of liabilities sold
Accounts payable		230
Accrued expenses and other current liabilities		1,430
Operating lease liabilities, current		869
Operating lease liabilities, non-current		8,044
Amounts attributable to liabilities sold		10,573
Total identifiable net assets sold		4,784
Less: accumulated other comprehensive loss		(155	)
Consideration, inclusive of cash transferred		25,218
Gain on sale of Freeline Therapeutics GmbH	$	20,279

License Revenue

9 Months Ended

Sep. 30, 2023

License Agreement [Abstract]

License Revenue

Prepaid Expenses and Other Current Assets

9 Months Ended

Sep. 30, 2023

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):


	September 30,		December 31,
	2023		2022
U.K. R&D tax credit	$	1,847	$	1,230
VAT receivable		976		1,373
Insurance		20		1,702
Prepaid clinical research organization costs		748		1,535
Other current assets		953		395
	$	4,544	$	6,235

Property and Equipment Net

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):


	September 30,			December 31,
	2023			2022
Office equipment and computers	$	929		$	751
Furniture & Fixtures		2,586			2,584
Laboratory equipment		3,278			3,140
Leasehold improvements		7,887			7,549
		14,680			14,024
Less: accumulated depreciation		(6,055	)		(5,017	)
	$	8,625		$	9,007

Depreciation and amortization expense was $1.1 million and $1.4 million for the nine months ended September 30, 2023 and 2022, respectively.

Other Non-current Assets

9 Months Ended

Sep. 30, 2023

Other Assets, Noncurrent Disclosure [Abstract]

Other Non-current Assets

Other non-current assets consisted of the following (in thousands):


	September 30,		December 31,
	2023		2022
Deferred offering costs	$	2,149	$	2,133
Restricted cash		—		1,327
Deferred tax asset		523		533
	$	2,672	$	3,993

Accrued Expenses and Other Liabilities

9 Months Ended

Sep. 30, 2023

Payables and Accruals [Abstract]

Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consisted of the following (in thousands):


	September 30,		December 31,
	2023		2022
Employee compensation and benefits costs	$	2,743	$	4,178
Research and development expenses		3,036		1,923
Consulting and professional services		1,351		1,215
Other liabilities		283		592
	$	7,413	$	7,908

Shareholders' Equity

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

Shareholders' Equity

Shareholders’ Equity

Ordinary Shares

As of September 30, 2023, the Company’s authorized capital consisted of 400,000,000 ordinary shares with a par value of £0.00001 per share.

ADS Ratio Change

Registered Direct Offering

Lincoln Park Capital

Open Market Sale AgreementSM

Deferred Shares

Deferred shares are not included in the Company’s potentially dilutive securities as they are not ordinary shares and have no conversion rights.

The table below reflects the number of ordinary shares and deferred shares issued and outstanding at September 30, 2023 and December 31, 2022.


	September 30,		December 31,
	2023		2022
Ordinary shares		65,369,206		65,113,575
Deferred shares of £0.00001		37,613		24,812
Deferred shares of £100,000		1		1
Total ordinary and deferred shares		65,406,820		65,138,388

Non-Cash Share-Based Compensation

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Non-Cash Share-Based Compensation

10.

Non-Cash Share-Based Compensation

2020 Equity Incentive Plan

2021 Equity Inducement Plan

2020 Employee Share Purchase Plan

Option Repricing

Employee Shares

A summary of the changes in the Employee Shares from December 31, 2022 through September 30, 2023 is as follows:


	Number of Shares			Weighted Average Grant Date Fair Value
Unvested balance as of December 31, 2022		16,309		$	11.33
Granted		—			—
Vested		(3,864	)		11.07
Forfeited		(11,642	)		11.91
Unvested balance as of September 30, 2023		803		$	13.05

Share Options Valuation


	For the Nine Months Ended September 30,
	2023
Expected option life (years)		5.8
Expected volatility		71.8	%
Risk-free interest rate		3.6	%
Expected dividend yield		—

Share Options


	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2022		7,918,500		$	4.76		8.40	$	—
Granted		4,031,696			0.20		—		457
Exercised		—			—		—		—
Expired		(665,081	)		13.67		—		—
Canceled or Forfeited		(1,789,783	)		2.86		—		—
Outstanding as of September 30, 2023		9,495,332		$	1.80		8.17	$	995
Exercisable as of September 30, 2023		3,017,640			4.48		6.53		211
Vested and expected to vest as of September 30, 2023		9,495,332		$	1.80		8.17	$	995

Restricted Share Units


	Number of RSUs			Weighted Average Grant Date Fair Value
Outstanding as of December 31, 2022		445,590		$	0.98
Granted		1,165,939			0.59
Vested and settled		(89,277	)		1.09
Canceled or forfeited		(351,821	)		0.85
Outstanding as of September 30, 2023		1,170,431		$	0.62

As of September 30, 2023, there was $0.6 million of unrecognized compensation cost related to unvested RSUs, which is expected to be recognized over a weighted-average period of 2.6 years.

Share-based Compensation Expense

Non-cash share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):


	For the Nine Months Ended September 30,
	2023		2022
Research and development	$	792	$	1,675
General and administrative		2,151		2,362
	$	2,943	$	4,037

Net Loss Per Share

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Net Loss Per Share

11.

Net Loss Per Share

Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts):


	September 30,
	2023			2022
Numerator
Net loss	$	(26,933	)	$	(65,973	)
Net loss attributable to ordinary shareholders—basic and diluted	$	(26,933	)	$	(65,973	)
Denominator
Weighted-average number of ordinary shares used in net loss per share - basic and diluted		65,217,110			57,384,985
Net loss per share attributable to ordinary shareholders— basic and diluted	$	(0.41	)	$	(1.15	)


	September 30,
	2023		2022
Unvested ordinary shares		803		21,493
Share options		9,495,332		8,171,164
Restricted share units		1,170,431		459,450
Total		10,666,566		8,652,107

Commitments and Contingencies

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

12.

Commitments and Contingencies

Legal Proceedings

Operating Lease Agreements

The following table summarizes the Company’s costs included in the statements of operations related to right of use lease assets entered into through September 30, 2023 and 2022 (in thousands):


	For the Nine Months Ended September 30,
Lease Cost	2023			2022
Operating lease cost
Research and development	$	1,744		$	10,459
General and administrative		815			237
Short-term lease cost		60			217
Sublease income		(50	)		(186	)
Total lease cost	$	2,569		$	10,727



	For the Nine Months Ended September 30,
Other Information	2023			2022
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	2,309		$	9,301
Weighted-average remaining lease term-operating leases		6.50			6.90
Weighted-average discount rate-operating leases		10.89	%		7.28	%

Contractual Obligations


Maturity of Operating Leases
Years Ended December 31,	Operating Leases
2023 (excluding the nine months ended September 30, 2023)		743
2024		1,942
2025		675
2026		654
2027		326
Thereafter		—
Total payments		4,340
Less: imputed interest		(383	)
Less: foreign exchange loss		31
Total	$	3,988

Indemnification Agreements

Related Party Transactions

9 Months Ended

Sep. 30, 2023

Related Party Transactions

13.

Related Party Transactions

The Company analyzed its transactions with related parties for the nine months ended September 30, 2023 and 2022, and determined it had the following material transactions.

Syncona

On March 10, 2022, the Company entered into a purchase agreement with its majority shareholder, Syncona Portfolio Limited, a subsidiary of Syncona Limited, and certain other existing shareholders providing for the issuance and sale by the Company of $26.1 million of the Company’s ADSs at a price of $1.05 per ordinary share, in a registered direct offering. The offering closed on March 15, 2022. The Company received net proceeds of approximately $24.2 million from the offering, after deducting offering expenses payable by the Company.

See Note 15, Subsequent Events, for further discussion of the definitive agreement entered into with a Syncona affiliate in November 2023.

Forcefield Therapeutics Limited

Syncona IP Holdco (2) Limited

See Note 4, License Revenue.

Restructuring Charges	9 Months Ended
Restructuring Charges	Sep. 30, 2023
Restructuring Charges [Abstract]
Restructuring Charges	14. Restructuring Charges During the first quarter of 2023, the Company completed a financial and organizational assessment to increase efficiencies and reduce operating expenses. As a result of this assessment, the Company reduced its U.S. and U.K. workforce by nearly 30%. For the nine months ended September 30, 2023, the Company incurred total expenses of $1.3 million, consisting of severance and termination-related costs, which were recognized as operating expenses.

Subsequent Events

9 Months Ended

Sep. 30, 2023

Subsequent Events [Abstract]

Subsequent Events

15.

Subsequent Events

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2023
Accounting Policies [Abstract]
Going Concern	Going Concern In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, the ability to secure additional capital to fund operations, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with government regulations. Product candidates currently under development require significant additional research and development efforts, including clinical testing and regulatory approval, prior to any commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from any product sales. The Company has funded its operations primarily with proceeds from the sale of its equity securities. As of September 30, 2023, the Company had unrestricted cash and cash equivalents of $29.5 million. The Company has incurred recurring losses since its inception including net losses of $26.9 million and $66.0 million for the nine months ended September 30, 2023 and 2022, respectively. In addition, the Company had an accumulated deficit of $472.3 million as of September 30, 2023. Net cash used in operating and investing activities was $20.8 million for the nine months ended September 30, 2023. The Company expects to continue to incur significant expenses and generate operating losses for the foreseeable future. These conditions indicate that there is substantial doubt regarding the Company's ability to continue as a going concern for at least 12 months from the issuance date of these unaudited condensed consolidated financial statements. As a result, the Company will need additional funding to support its continuing operations. There can be no assurances, however, that additional funding will be available on favorable terms, or at all. If adequate funds are not available, the Company will be required to further reduce headcount as well as spending and potentially delay, limit, reduce or terminate its product research and development efforts in order to enable it to meet its obligations as they fall due for the foreseeable future. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.
License Revenue	License Revenue The Company accounts for its revenues pursuant to the provisions of ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The Company has no products approved for commercial sale and has not generated any revenue from commercial product sales. The revenue earned to date has been generated solely from an out-licensing agreement. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the arrangement within the scope of ASC 606, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.
License Fees and Multiple Element Arrangements	License Fees and Multiple Element Arrangements If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license at such time as the license is transferred to the licensee and the licensee is able to use, and benefit from, the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Appropriate methods of measuring progress include output methods and input methods. In determining the appropriate method for measuring progress, the Company considers the nature of service that the Company promises to transfer to the customer. When the Company decides on a method of measurement, the Company will apply that single method of measuring progress for each performance obligation satisfied over time and will apply that method consistently to similar performance obligations and in similar circumstances.
Contingent Research Milestone Payments	Contingent Research Milestone Payments ASC 606 constrains the amount of variable consideration included in the transaction price in that either all, or a portion, of an amount of variable consideration should be included in the transaction price. The variable consideration amount should be included only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The assessment of whether variable consideration should be constrained is largely a qualitative one that has two elements: the likelihood of a change in estimate, and the magnitude thereof. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized is not significant. If the consideration in a contract includes a variable amount, the Company will estimate the amount of consideration in exchange for transfer of promised goods or services. The consideration also can vary if the Company’s entitlement to the consideration is contingent on the occurrence or non-occurrence of a future event. The Company considers contingent research milestone payments to fall under the scope of variable consideration, which should be estimated for revenue recognition purposes at the inception of the contract and reassessed ongoing at the end of each reporting period. If the Company determines that variable consideration should be constrained, the variable consideration is not included as part of the transaction price. This includes an assessment of the probability that all or some of the milestone revenue could be reversed when the uncertainty around whether or not the achievement of each milestone is resolved, and the amount of reversal could be significant. The Company considers all relevant factors in accordance with U.S. GAAP when assessing whether variable consideration should be constrained and no one factor is determinative.
Royalty Revenue	Royalty Revenue For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and in which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

Sale of Freeline Therapeutics GmbH (Tables)

9 Months Ended

Sep. 30, 2023

Discontinued Operations and Disposal Groups [Abstract]

Summary of Company's Book Value of Assets and Liabilities Sold

he table below sets forth the book value of the Freeline Therapeutics GmbH assets and liabilities sold along with the calculation of the gain on sale based on the cash consideration received.


	(in thousands)
Book value of assets sold
Cash and cash equivalents	$	1,015
Prepaid expenses and other current assets		414
Property and equipment, net		5,470
Operating lease right of use assets		8,455
Other non-current assets		3
Amounts attributable to assets sold		15,357
Book value of liabilities sold
Accounts payable		230
Accrued expenses and other current liabilities		1,430
Operating lease liabilities, current		869
Operating lease liabilities, non-current		8,044
Amounts attributable to liabilities sold		10,573
Total identifiable net assets sold		4,784
Less: accumulated other comprehensive loss		(155	)
Consideration, inclusive of cash transferred		25,218
Gain on sale of Freeline Therapeutics GmbH	$	20,279

Prepaid Expenses and Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2023

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):


	September 30,		December 31,
	2023		2022
U.K. R&D tax credit	$	1,847	$	1,230
VAT receivable		976		1,373
Insurance		20		1,702
Prepaid clinical research organization costs		748		1,535
Other current assets		953		395
	$	4,544	$	6,235

Property and Equipment Net (Tables)

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

Summary of Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):


	September 30,			December 31,
	2023			2022
Office equipment and computers	$	929		$	751
Furniture & Fixtures		2,586			2,584
Laboratory equipment		3,278			3,140
Leasehold improvements		7,887			7,549
		14,680			14,024
Less: accumulated depreciation		(6,055	)		(5,017	)
	$	8,625		$	9,007

Other Non-current Assets (Tables)

9 Months Ended

Sep. 30, 2023

Other Assets, Noncurrent Disclosure [Abstract]

Summary of Other Non-current Assets

Other non-current assets consisted of the following (in thousands):


	September 30,		December 31,
	2023		2022
Deferred offering costs	$	2,149	$	2,133
Restricted cash		—		1,327
Deferred tax asset		523		533
	$	2,672	$	3,993

Accrued Expenses and Other Liabilities (Tables)

9 Months Ended

Sep. 30, 2023

Payables and Accruals [Abstract]

Schedule of Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consisted of the following (in thousands):


	September 30,		December 31,
	2023		2022
Employee compensation and benefits costs	$	2,743	$	4,178
Research and development expenses		3,036		1,923
Consulting and professional services		1,351		1,215
Other liabilities		283		592
	$	7,413	$	7,908

Shareholders' Equity (Tables)

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

Summary of Ordinary Shares, and Deferred Shares Issued

The table below reflects the number of ordinary shares and deferred shares issued and outstanding at September 30, 2023 and December 31, 2022.


	September 30,		December 31,
	2023		2022
Ordinary shares		65,369,206		65,113,575
Deferred shares of £0.00001		37,613		24,812
Deferred shares of £100,000		1		1
Total ordinary and deferred shares		65,406,820		65,138,388

Non-Cash Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Summary of Changes in Employee Shares

A summary of the changes in the Employee Shares from December 31, 2022 through September 30, 2023 is as follows:


	Number of Shares			Weighted Average Grant Date Fair Value
Unvested balance as of December 31, 2022		16,309		$	11.33
Granted		—			—
Vested		(3,864	)		11.07
Forfeited		(11,642	)		11.91
Unvested balance as of September 30, 2023		803		$	13.05

Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Share Options Granted to Employees and Directors


	For the Nine Months Ended September 30,
	2023
Expected option life (years)		5.8
Expected volatility		71.8	%
Risk-free interest rate		3.6	%
Expected dividend yield		—

Summary of Share Options

Share Options


	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2022		7,918,500		$	4.76		8.40	$	—
Granted		4,031,696			0.20		—		457
Exercised		—			—		—		—
Expired		(665,081	)		13.67		—		—
Canceled or Forfeited		(1,789,783	)		2.86		—		—
Outstanding as of September 30, 2023		9,495,332		$	1.80		8.17	$	995
Exercisable as of September 30, 2023		3,017,640			4.48		6.53		211
Vested and expected to vest as of September 30, 2023		9,495,332		$	1.80		8.17	$	995

Summary of Activity Related to RSUs

The following table summarizes the activity related to RSUs from December 31, 2022, through September 30, 2023:


	Number of RSUs			Weighted Average Grant Date Fair Value
Outstanding as of December 31, 2022		445,590		$	0.98
Granted		1,165,939			0.59
Vested and settled		(89,277	)		1.09
Canceled or forfeited		(351,821	)		0.85
Outstanding as of September 30, 2023		1,170,431		$	0.62

Summary of Non-Cash Share-Based Compensation Expense

Non-cash share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):


	For the Nine Months Ended September 30,
	2023		2022
Research and development	$	792	$	1,675
General and administrative		2,151		2,362
	$	2,943	$	4,037

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Net Loss Per Share Attributable to Ordinary Shareholders

Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows (in thousands, except share and per share amounts):


	September 30,
	2023			2022
Numerator
Net loss	$	(26,933	)	$	(65,973	)
Net loss attributable to ordinary shareholders—basic and diluted	$	(26,933	)	$	(65,973	)
Denominator
Weighted-average number of ordinary shares used in net loss per share - basic and diluted		65,217,110			57,384,985
Net loss per share attributable to ordinary shareholders— basic and diluted	$	(0.41	)	$	(1.15	)

Schedule of Potential Ordinary Shares Excluded from Computation of Diluted Net Loss Per Share

The Company excluded the following potential ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to ordinary shareholders for the nine months ended September 30, 2023 and 2022 because including them would have had an anti-dilutive effect:


	September 30,
	2023		2022
Unvested ordinary shares		803		21,493
Share options		9,495,332		8,171,164
Restricted share units		1,170,431		459,450
Total		10,666,566		8,652,107

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

Summary of Lease Cost

The following table summarizes the Company’s costs included in the statements of operations related to right of use lease assets entered into through September 30, 2023 and 2022 (in thousands):


	For the Nine Months Ended September 30,
Lease Cost	2023			2022
Operating lease cost
Research and development	$	1,744		$	10,459
General and administrative		815			237
Short-term lease cost		60			217
Sublease income		(50	)		(186	)
Total lease cost	$	2,569		$	10,727

Summary of Right of Use Lease Assets



	For the Nine Months Ended September 30,
Other Information	2023			2022
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$	2,309		$	9,301
Weighted-average remaining lease term-operating leases		6.50			6.90
Weighted-average discount rate-operating leases		10.89	%		7.28	%

Schedule of Future Minimum Lease Payments


Maturity of Operating Leases
Years Ended December 31,	Operating Leases
2023 (excluding the nine months ended September 30, 2023)		743
2024		1,942
2025		675
2026		654
2027		326
Thereafter		—
Total payments		4,340
Less: imputed interest		(383	)
Less: foreign exchange loss		31
Total	$	3,988

Nature of the Business - Additional Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net losses	$ (26,933)	$ (65,973)
Accumulated deficit	472,286		$ 445,353
Net cash used in operating and investing activities	20,800
Cash and cash equivalents	$ 29,452	$ 65,848	$ 47,279

Sale of Freeline Therapeutics GmbH - Additional Information (Details) $ in Thousands		9 Months Ended
	Feb. 08, 2023 USD ($) Employees	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of Freeline Therapeutics GmbH		$ 20,279
Restructuring charges		1,339
Prepaid Expenses
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
FTE costs paid		2,600
Freeline Therapeutics Gmbh
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Aggregate cash purchase price	$ 25,218
Gain on sale of Freeline Therapeutics GmbH	20,279
Foreign currency translation losses	$ 200
Number of full-time employee equivalents \| Employees	15
Committed payments under services agreement for next year		$ 3,100	$ 2,200
Committed payments under services agreement for year two			$ 3,100
Freeline Therapeutics Gmbh \| Minimum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Restructuring charges	$ 7,900

Sale of Freeline Therapeutics GmbH - Summary of Company's Book Value of Assets And Liabilities Sold (Details) - USD ($) $ in Thousands		9 Months Ended
	Feb. 08, 2023	Sep. 30, 2023	Dec. 31, 2022
Book value of liabilities sold
Amounts attributable to liabilities sold			$ 10,337
Less: accumulated other comprehensive loss		$ (1,567)	$ (3,151)
Gain on sale of Freeline Therapeutics GmbH		$ 20,279
Freeline Therapeutics Gmbh
Book value of assets sold
Cash and cash equivalents	$ 1,015
Prepaid expenses and other current assets	414
Property and equipment, net	5,470
Operating lease right of use assets	8,455
Other non-current assets	3
Amounts attributable to assets sold	15,357
Book value of liabilities sold
Accounts payable	230
Accrued expenses and other current liabilities	1,430
Operating lease liabilities, current	869
Operating lease liabilities, non-current	8,044
Amounts attributable to liabilities sold	10,573
Total identifiable net assets sold	4,784
Less: accumulated other comprehensive loss	(155)
Consideration, inclusive of cash transferred	25,218
Gain on sale of Freeline Therapeutics GmbH	$ 20,279

License Revenue - Additional Information (Details) $ in Thousands, £ in Millions			9 Months Ended
	Mar. 24, 2023 USD ($)	Mar. 24, 2023 GBP (£)	Sep. 30, 2023 USD ($)	Sep. 30, 2023 GBP (£)	Mar. 24, 2023 GBP (£)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue			$ 622
Syncona IP Holdco (2) Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront non-refundable payment	$ 600	£ 0.5
Maximum milestone payments to be received	$ 15,600				£ 12.5
Syncona IP Holdco (2) Limited \| License
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue			$ 600	£ 0.5

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
U.K. R&D tax credit	$ 1,847	$ 1,230
VAT receivable	976	1,373
Insurance	20	1,702
Prepaid clinical research organization costs	748	1,535
Other current assets	953	395
Prepaid expenses and other current assets	$ 4,544	$ 6,235

Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 14,680	$ 14,024
Less: accumulated depreciation	(6,055)	(5,017)
Property plant and equipment net	8,625	9,007
Office Equipment and Computers
Property Plant And Equipment [Line Items]
Property and equipment, gross	929	751
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,586	2,584
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	3,278	3,140
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 7,887	$ 7,549

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 1.1	$ 1.4

Other Non-current Assets - Summary of Other Non-current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Other Assets, Noncurrent [Abstract]
Deferred offering costs	$ 2,149	$ 2,133
Restricted cash		1,327
Deferred tax asset	523	533
Other Non-current assets	$ 2,672	$ 3,993

Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Employee Compensation and benefits costs	$ 2,743	$ 4,178
Research and development expenses	3,036	1,923
Consulting and professional services	1,351	1,215
Other liabilities	283	592
Accrued expenses and other liabilities	$ 7,413	$ 7,908

Shareholders' Equity - Additional Information (Details)					9 Months Ended		12 Months Ended
Shareholders' Equity - Additional Information (Details)	May 12, 2023 USD ($) shares	Mar. 18, 2022 USD ($) shares	Mar. 10, 2022 USD ($) $ / shares shares	Nov. 17, 2021 USD ($)	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) shares	Sep. 30, 2023 £ / shares	Dec. 31, 2022 £ / shares	Sep. 30, 2022 £ / shares
Class Of Stock [Line Items]
Ordinary shares, authorized \| shares					400,000,000		400,000,000
Ordinary shares, par value \| £ / shares								£ 0.00001	£ 0.00001	£ 0.00001
Common stock, voting rights					Each holder of ordinary shares is entitled to one vote per ordinary share
Dividends declared or paid					$ 0
Number of ordinary shares for each ADS \| shares	15
Proceeds from issuance of ordinary shares						$ 27,328,000
Stock Issued						$ 963,000
Other non-current assets					$ 2,672,000		$ 3,993,000
Deferred shares conversion rights					no conversion rights
American Depository Shares \| Syncona Portfolio Limited
Class Of Stock [Line Items]
Stock issued during period, shares \| shares			24,857,144
Stock issued during period, value			$ 26,100,000
Price per ordinary share \| $ / shares			$ 1.05
Proceeds from issuance of ordinary shares			$ 24,200,000
American Depository Shares \| Lincoln Park Capital Fund, LLC
Class Of Stock [Line Items]
Stock issued during period, shares \| shares		954,208			0
Sale of stock period		36 months
Stock Issued		$ 1,000,000.0
Other non-current assets		200,000
American Depository Shares \| Lincoln Park Capital Fund, LLC \| Maximum
Class Of Stock [Line Items]
Value of stock available for sale under the purchase agreement		$ 35,000,000.0
American Depository Shares \| Jefferies LLC \| Open Market Sale Agreement
Class Of Stock [Line Items]
Stock issued during period, shares \| shares					0		3,037,616
Proceeds from issuance of ordinary shares							$ 3,200,000
American Depository Shares \| Jefferies LLC \| Open Market Sale Agreement \| At-the-Market Offerings
Class Of Stock [Line Items]
Maximum offering Sales proceeds from issuance of common stock				$ 75,000,000
American Depository Shares \| General and Administrative
Class Of Stock [Line Items]
Depositary fees paid	$ 2,000,000
Deferred Shares
Class Of Stock [Line Items]
Deferred shares, par value \| £ / shares								£ 0.00001	£ 0.00001

Shareholders' Equity - Summary of Ordinary Shares, and Deferred Shares Issued (Details) - shares	Sep. 30, 2023	Dec. 31, 2022
Class Of Stock [Line Items]
Ordinary shares	65,369,206	65,113,575
Total ordinary and deferred shares	65,406,820	65,138,388
Ordinary Shares
Class Of Stock [Line Items]
Ordinary shares	65,369,206	65,113,575
Deferred Shares
Class Of Stock [Line Items]
Deferred shares	37,613	24,812
Deferred Shares One
Class Of Stock [Line Items]
Deferred shares	1	1

Shareholders' Equity - Summary of Ordinary Shares, and Deferred Shares Issued (Parenthetical) (Details) - £ / shares	Sep. 30, 2023	Dec. 31, 2022
Deferred Shares
Class of Stock [Line Items]
Deferred shares, par value	£ 0.00001	£ 0.00001
Deferred Shares One
Class of Stock [Line Items]
Deferred shares, par value	£ 100,000	£ 100,000

Non-Cash Share-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions						9 Months Ended
	Jun. 29, 2023	Jun. 28, 2023	Jan. 01, 2023	Jan. 01, 2022	Jul. 31, 2020	Sep. 30, 2023	Sep. 30, 2022	May 12, 2023	Sep. 27, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of ordinary shares for each ADS								15
Unrecognized compensation cost related to unvested employee shares outstanding						$ 0.1
Weighted-average period of unvested employee shares outstanding						1 year
Share Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost related to unvested employee shares outstanding						$ 5.5
Weighted-average period of unvested employee shares outstanding						2 years 2 months 12 days
Weighted average grant-date fair value of share options granted						$ 0.20	$ 0.73
Weighted average grant-date fair value of share options vested						$ 2.81	$ 7.30
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
General vesting period						1 year
Unrecognized compensation cost related to unvested employee shares outstanding						$ 0.6
Weighted-average period of unvested employee shares outstanding						2 years 7 months 6 days
Option Repricing
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of option granted per ADS	$ 2.42
Incremental share based compensation expense						$ 0.4
Incremental share based compensation expense, vested share option awards						0.1
Incremental share based compensation expense, unvested share option awards						$ 0.3
2020 Employee Share Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of ordinary shares subject to automatic increase in outstanding ordinary shares on each year					1.00%
Terms of share option plan						The ESPP provides for an annual increase beginning on January 1, 2022 in an amount equal to the least of (i) 347,447 ordinary shares, (ii) 1% of the total number of ordinary shares outstanding on December 31st of the prior calendar year or (iii) such fewer number of ordinary shares as the board of directors may designate prior to the applicable January 1st date.
Number of ordinary shares subject to automatic increase in outstanding ordinary shares on each year			347,447		347,447
Ordinary shares reserved for issuance					347,447	393,278
Purchase price of ordinary shares, percentage of fair market value					85.00%
Percentage of employee's compensation eligible					15.00%
Number of shares purchased						217,755
2020 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of equity awards authorized					5,898,625
Term of ordinary shares subject to automatic increase in outstanding ordinary shares on each year					10 years
Percentage of ordinary shares subject to automatic increase in outstanding ordinary shares on each year					4.00%
Terms of share option plan						Additionally, the number of ordinary shares reserved for issuance under the 2020 Plan automatically increases on January 1st of each year, for a period of not more than ten years, by an amount equal to the lesser of (i) 4% of the total number of ordinary shares outstanding on December 31st of the prior calendar year or (ii) such fewer number of ordinary shares as the board of directors may designate prior to the applicable January 1st date.
Number of ordinary shares subject to automatic increase in outstanding ordinary shares on each year			2,596,620	1,434,184
Service based options, vesting period						4 years
Vesting percentage						25.00%
General vesting period						3 years
Ordinary shares reserved for issuance						2,252,316
Inducement Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of equity awards authorized									3,400,000
Ordinary shares reserved for issuance						1,677,200
Grants issued						0
2021 Equity Inducement Plan and 2020 Equity Incentive Plan \| Option Repricing
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of option granted per ordinary share		$ 0.42
Exercise price of option granted per ADS		$ 6.27

Non-Cash Share-Based Compensation - Summary of Changes in Employee Shares (Details) - Performance and Service Based	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Unvested balance \| shares	16,309
Number of Shares, Vested \| shares	(3,864)
Number of Shares, Forfeited \| shares	(11,642)
Number of Shares, Unvested balance \| shares	803
Weighted Average Grant Date Fair Value, Unvested balance \| $ / shares	$ 11.33
Weighted Average Grant Date Fair Value, Vested \| $ / shares	11.07
Weighted Average Grant Date Fair Value, Forfeited \| $ / shares	11.91
Weighted Average Grant Date Fair Value, Unvested balance \| $ / shares	$ 13.05

Non-Cash Share-Based Compensation - Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Share Options Granted to Employees and Directors (Details)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Expected option life (years)	5 years 9 months 18 days
Expected volatility	71.80%
Risk-free interest rate	3.60%

Non-Cash Share-Based Compensation - Summary of Share Options (Details) - Share Options - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Outstanding beginning balance	7,918,500
Number of Shares, Granted	4,031,696
Number of Shares, Expired	(665,081)
Number of Shares, Canceled or Forfeited	(1,789,783)
Number of Shares, Outstanding ending balance	9,495,332	7,918,500
Number of Shares, Exercisable as of September 30, 2023	3,017,640
Number of Shares, Vested and expected to vest as of September 30, 2023	9,495,332
Weighted Average Exercise Price, Outstanding beginning balance	$ 4.76
Weighted Average Exercise Price, Granted	0.2
Weighted Average Exercise Price, Expired	13.67
Weighted Average Exercise Price, Canceled or Forfeited	2.86
Weighted Average Exercise Price, Outstanding ending balance	1.8	$ 4.76
Weighted Average Exercise Price, Exercisable as of September 30, 2023	4.48
Weighted Average Exercise Price, Vested and expected to vest as of September 30, 2023	$ 1.8
Weighted Average Remaining Contractual Term (in years), Outstanding	8 years 2 months 1 day	8 years 4 months 24 days
Weighted Average Remaining Contractual Term (in years), Exercisable as of September 30, 2023	6 years 6 months 10 days
Weighted Average Remaining Contractual Term (in years), Vested and expected to vest as of September 30, 2023	8 years 2 months 1 day
Aggregate Intrinsic Value, Outstanding	$ 995	$ 457
Aggregate Intrinsic Value, Exercisable as of September 30, 2023	211
Aggregate Intrinsic Value, Vested and expected to vest as of September 30, 2023	$ 995

Non-Cash Share-Based Compensation - Summary of Activity Related to RSUs (Details) - RSUs	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Unvested balance \| shares	445,590
Number of RSUs, Granted \| shares	1,165,939
Number of RSUs, Vested and settled \| shares	(89,277)
Number of Shares, Forfeited \| shares	(351,821)
Number of Shares, Unvested balance \| shares	1,170,431
Weighted Average Grant Date Fair Value, Unvested balance \| $ / shares	$ 0.98
Weighted Average Grant Date Fair Value, Granted \| $ / shares	0.59
Weighted Average Grant Date Fair Value, Vested and settled \| $ / shares	1.09
Weighted Average Grant Date Fair Value, Forfeited \| $ / shares	0.85
Weighted Average Grant Date Fair Value, Unvested balance \| $ / shares	$ 0.62

Non-Cash Share-Based Compensation - Summary of Non-Cash Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Non-cash share-based compensation expense	$ 2,943	$ 4,037
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Non-cash share-based compensation expense	792	1,675
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Non-cash share-based compensation expense	$ 2,151	$ 2,362

Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Ordinary Shareholders (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Numerator
Net loss	$ (26,933)	$ (65,973)
Net loss attributable to ordinary shareholders-basic	(26,933)	(65,973)
Net loss attributable to ordinary shareholders-diluted	$ (26,933)	$ (65,973)
Denominator
Weighted average number of ordinary shares used in net loss per share - Basic	65,217,110	57,384,985
Weighted average number of ordinary shares used in net loss per share - Diluted	65,217,110	57,384,985
Net loss per share attributable to ordinary shareholders-basic	$ (0.41)	$ (1.15)
Net loss per share attributable to ordinary shareholders-diluted	$ (0.41)	$ (1.15)

Net Loss Per Share - Schedule of Potential Ordinary Shares Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares excluded from computation of diluted net loss per share	10,666,566	8,652,107
Unvested Ordinary Shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares excluded from computation of diluted net loss per share	803	21,493
Share Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares excluded from computation of diluted net loss per share	9,495,332	8,171,164
RSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Ordinary shares excluded from computation of diluted net loss per share	1,170,431	459,450

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands		9 Months Ended		12 Months Ended
	May 18, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Commitments And Contingencies [Line Items]
Operating lease right-of-use assets		$ 3,926		$ 6,014
Operating lease liabilities		3,988
Gain on lease termination			$ 5,307
Gain on litigation settlement		2,227
Freeline Therapeutics Gmbh
Commitments And Contingencies [Line Items]
Committed payments under services agreement for remainder fiscal period		2,200
Committed payments under services agreement for next year		3,100		2,200
Committed payments under services agreement		7,900
Manufacturing Agreement
Commitments And Contingencies [Line Items]
Annual minimum purchase commitment		6,000
Operating Lease Agreements
Commitments And Contingencies [Line Items]
Operating lease right-of-use assets				35,600
Operating lease liabilities				40,300
Gain on lease termination				$ 5,300
Brammer Bio MA, LLC
Commitments And Contingencies [Line Items]
Annual capacity access fee		$ 10,000
Settlement paid	$ 2,250
Discharged liabilities reversed	5,100
Prepaid expenses reversed	600
Gain on litigation settlement	$ 2,200

Commitments and Contingencies - Summary of Lease Cost (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating lease cost
Short-term lease cost	$ 60	$ 217
Sublease income	(50)	(186)
Total lease cost	2,569	10,727
Research and Development
Operating lease cost
Operating lease cost	1,744	10,459
General and Administrative
Operating lease cost
Operating lease cost	$ 815	$ 237

Commitments and Contingencies - Summary of Right of Use Lease Assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Other Information [Abstract]
Operating cash flows from operating leases	$ 2,309	$ 9,301
Weighted-average remaining lease term-operating leases	6 years 6 months	6 years 10 months 24 days
Weighted-average discount rate-operating leases	10.89%	7.28%

Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2023 (excluding the nine months ended September 30, 2023)	$ 743
2024	1,942
2025	675
2026	654
2027	326
Total payments	4,340
Less: imputed interest	(383)
Less: foreign exchange loss	31
Total	$ 3,988

Related Party Transactions - Additional Information (Details) $ / shares in Units, $ in Thousands, £ in Millions				9 Months Ended
	Mar. 21, 2023 USD ($)	Mar. 21, 2023 GBP (£)	Mar. 10, 2022 USD ($) $ / shares	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Related Party Transaction [Line Items]
Proceeds from issuance of ordinary shares					$ 27,328
Research and development expenses				$ 25,508	$ 53,561
Syncona Portfolio Limited \| American Depository Shares
Related Party Transaction [Line Items]
Stock issued during period, value			$ 26,100
Price per ordinary share \| $ / shares			$ 1.05
Proceeds from issuance of ordinary shares			$ 24,200
Forcefield Therapeutics Limited
Related Party Transaction [Line Items]
Upfront Payment	$ 600	£ 0.5
Research and development expenses				$ 600
Forcefield Therapeutics Limited \| Maximum
Related Party Transaction [Line Items]
Development and regulatory milestone payments	$ 22,800	£ 18.3

Restructuring Charges - Additional Information (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Restructuring Charges [Abstract]
Reduction in workforce, percentage	30.00%
Restructuring expense	$ 1,339

Subsequent Events - Additional Information (Details) - Subsequent Events - Implementation Agreement - Syncona Portfolio Limited $ / shares in Units, $ in Millions	Nov. 22, 2023 USD ($) $ / shares
American Depository Shares
Subsequent Event [Line Items]
Acquisition share price in cash \| $ / shares	$ 6.5
Fixed Rate Convertible Loan Notes Due 2024
Subsequent Event [Line Items]
Aggregate principal amount \| $	$ 10.0
Additional aggregate principal amount \| $	$ 5.0
Interest rate	12.00%
Fixed Rate Convertible Loan Notes Due 2024 \| American Depository Shares
Subsequent Event [Line Items]
Conversion price \| $ / shares	$ 6.5